

## Review Article

# Gut–brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease

Abautret-Daly Á, Dempsey E, Parra-Blanco A, Medina C, Harkin A.  
Gut–brain actions underlying comorbid anxiety and depression associated with inflammatory bowel disease.

**Introduction:** Inflammatory bowel disease (IBD) is a chronic relapsing and remitting disorder characterised by inflammation of the gastrointestinal tract. There is a growing consensus that IBD is associated with anxiety- and depression-related symptoms. Psychological symptoms appear to be more prevalent during active disease states with no difference in prevalence between Crohn's disease and ulcerative colitis. Behavioural disturbances including anxiety- and depression-like symptoms have also been observed in animal models of IBD.

**Results:** The likely mechanisms underlying the association are discussed with particular reference to communication between the gut and brain. The close bidirectional relationship known as the gut–brain axis includes neural, hormonal and immune communication links. Evidence is provided for a number of interacting factors including activation of the inflammatory response system in the brain, the hypothalamic–pituitary–adrenal axis, and brain areas implicated in altered behaviours, changes in blood brain barrier integrity, and an emerging role for gut microbiota and response to probiotics in IBD.

**Discussion:** The impact of psychological stress in models of IBD remains somewhat conflicted, however, it is weighted in favour of stress or early stressful life events as risk factors in the development of IBD, stress-induced exacerbation of inflammation and relapse.

**Conclusion:** It is recommended that patients with IBD be screened for psychological disturbance and treated accordingly as intervention can improve quality of life and may reduce relapse rates.

Áine Abautret-Daly<sup>1,2,†</sup>,  
Elaine Dempsey<sup>1,2,†</sup>,  
Adolfo Parra-Blanco<sup>3</sup>,  
Carlos Medina<sup>3,4</sup>,  
Andrew Harkin<sup>1,2</sup>

<sup>1</sup>Neuropsychopharmacology Research Group, Trinity College Institute of Neuroscience, Trinity College, Dublin, Ireland; <sup>2</sup>School of Pharmacy & Pharmaceutical Sciences, Trinity College, Dublin, Ireland; <sup>3</sup>Department of Gastroenterology, Hospital Central de Asturias, Oviedo, Spain; and <sup>4</sup>Trinity Biosciences Institute, Trinity College, Dublin, Ireland

†† Áine Abautret-Daly and Elaine Dempsey contributed equally to this work.

Keywords: anxiety; colitis; depression; gut–brain axis; inflammatory bowel disease

Andrew Harkin, School of Pharmacy & Pharmaceutical Sciences and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin 2, Ireland.

Tel: +353 1 896 8575;

Fax: +353 1 896 2821;

E-mail: aharkin@tcd.ie

Accepted for publication February 3, 2017

First published online March 8, 2017

### Summations

- Inflammatory bowel disease (IBD) patients are at an increased risk for developing an anxiety- or depression-related disorder.
- Animal models of IBD are a useful tool in understanding the physiological changes that occur in the brain in response to gastrointestinal (GI) inflammation.
- Due to the bidirectionality of the gut–brain axis stress, anxiety or depression may in turn exacerbate or trigger IBD. Treatment of psychological symptoms may improve health-related quality of life (HRQOL) and relapse rates for patients.

### Considerations

- The increased risk of psychological symptoms during active IBD is generally agreed upon in the literature, however, further work is required during disease remission. It is possible that persistent psychological symptoms occur as a result of ongoing irritable bowel syndrome (IBS)-like symptoms.
- No one animal model or behavioural test can accurately represent the human condition in IBD or psychological illness. Translational tools such as magnetic resonance imaging (MRI) should be used for more direct comparisons between models and humans.
- The link between stress and IBD remains controversial and requires further study. The use of psychological treatments for IBD is unlikely to replace traditional anti-inflammatory treatments. Management of GI symptoms may also improve psychological outcomes.

### Introduction

IBD is a chronic relapsing and remitting disorder of the GI tract. Crohn's disease (CD) and ulcerative colitis (UC) are the two main subtypes of IBD. CD and UC have similar symptomatology, however, CD symptoms can depend on the site of inflammation. Symptoms common to both CD and UC include abdominal pain/cramping, loose stools, diarrhoea, bloody stools, rectal bleeding, fatigue and a loss of appetite or food avoidance. Extra-intestinal manifestations of IBD can affect joints, the skin and eyes (1). IBD patients are also at a higher risk of developing colorectal cancer (CRC) compared with the general population (2). CD and UC differ mainly in their histology and in terms of their location within the GI tract. CD affects all layers of the gut wall, whereas in UC inflammation is usually confined to the mucosa. The formation of intestinal granulomas and fistulae are hallmarks of CD. Inflammation in UC usually remains in the rectum and colon, whereas CD can affect any part of the GI tract, however, most commonly involves ileocaecal inflammation (3,4).

The disease burden of IBD is challenging for patients and not only includes the physiological manifestations of the disease but also psychological and social burden. An IMPACT survey commissioned by the European Federation of Crohn's and Ulcerative Colitis Associations in late 2010 assessed the impact that IBD can have on patients in terms of medical implications, emotional well-being, education and work, and overall quality of life. Almost half (48%) of European IBD patients surveyed indicated that even between flare-ups their lives are negatively affected by symptoms of IBD (5). Although IBD can occur at any age, the disease has a peak in incidence rates in younger people between the ages of 15 and 30 years, meaning that the majority of patients are faced with this diagnosis during the most productive years of life. In CD, incidence declines sharply following this peak, however, in UC, peak incidence typically occurs 5 years later than in CD and plateaus, particularly in males, in whom incidence does not significantly decrease until the seventh decade of life (6).

The aetiology of IBD remains unknown, however, the consensus is that immune dysfunction and inflammation occurs as a response to an environmental trigger in a genetically susceptible host. IBD is an incurable yet treatable disease typically managed with drugs (aminosalicylates, systemic corticosteroids and immunosuppressants) and surgery (such as bowel resection for CD or colectomy with ileostomy or ileo-anal pouch anastomosis) if necessary (7,8). Surgery will generally be required in 70–80% of CD patients and up to 30% of UC patients (9). Surgery may be curative for UC, whereas inflammation usually recurs following surgery in CD (10). Mortality for IBD is slightly higher than the general population with a UK study of over 16 000 IBD patients with age- and sex-matched controls indicating 54% excess mortality associated with IBD diagnosis (11).

### Comorbid anxiety and depression in IBD

Historically there has been a long-standing interest in the comorbidity of psychological well-being, psychiatric illness and personality differences associated with IBD (12–15) in patients of all age groups. Many early studies in adults and children came to the conclusion that both UC and CD are related to higher incidence of psychological symptoms (16–18). Of particular interest is the study by Addolorato et al. (18) as only patients naïve to steroid treatment and surgical intervention were included, and again IBD patients had significantly higher expression of depressive symptoms than controls (41.9% and 50% of CD and UC patients, respectively, show depressive symptoms compared with 11.1% of controls). They also report an association between mood and disease activation.

In a recent systematic review of the comorbidity of psychological disorders with IBD, Mikocka-Walus et al. (19) evaluated 66 articles published between 2005 and 2014. Rates of anxiety and depression were estimated to be greater in IBD patients compared with healthy individuals, with rates of both being

higher during the active IBD phase compared with remission. Mean rates of anxiety and depression were significantly higher in CD compared with UC but only modestly so.

Validated questionnaires including the Hospital Anxiety and Depression Scales (HADS), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI) and Hamilton anxiety and depression scales have been used to confirm an increased risk of psychological disturbances in IBD patients (20–23). Differences between studies suggest that factors such as the level of disease activity may influence anxiety and depression scores. Depression and/or anxiety are consistently reported to be increased in the active phase of IBD (20,24–26).

A detailed summary of reports documenting anxiety and depression symptoms in IBD patients is summarised in Table 1.

#### Anxiety/depression in paediatric IBD

Increased risk for psychiatric disorders is not unique to adults with IBD; adolescents and children with IBD are also reported to have increased risk of anxiety and depression. In a large paediatric patient study; Loftus et al. (46) compared 2144 paediatric patients with CD to 10 720 age- and sex-matched controls. As with the adult studies, young patients with CD were found to be at greater risk of developing persistent anxiety disorders and depression. Interestingly, they found steroids to be a risk factor for developing anxiety disorders, however, even after controlling for this, CD itself was found to be a risk factor for mood disorders. Their analysis of prescription drug types suggest that the psychiatric conditions observed in the CD patients are being managed to some degree, as the usage of antidepressants, anti-psychotics, anxiolytics, mood stabilisers and benzodiazepines was higher in CD patients compared with controls (35). Szigethy et al. (34) have reported that three distinct profiles of depression exist in youths with IBD ( $n = 217$ ): mild depression (in 75% of participants) encompassing diverse, low-grade depressive symptoms and possessing the highest quality of life; somatic depression (in 19%) displaying severe fatigue, appetite change, anhedonia, decreased motor activity and depressed mood with concurrent high-dose steroid therapy and the highest IBD activity; and cognitive despair (in 6%) with the highest rates of self-reported depressive symptoms, ostomy placements and anxiety. Patients in the cognitive despair group reported IBD symptoms in the relative absence of inflammation and rated as the highest of the three profile groups on measures of morbid and suicidal

ideations. As a result, they suggested that subgroup-specific interventions may be needed when treating depression in youths with IBD.

#### Anxiety/depression in active IBD versus remission

In a small case-control study which included healthy controls and CD patients with active disease, investigators reported increased anxiety and depression during active IBD (23). A third group of CD patients, being treated with a thiopurinic immunomodulator, was also included. Interestingly, thiopurinic-induced remission restored psychological well-being to normal range in CD patients. In a more recent retrospective study, IBD patients treated with anti-tumour necrosis factor (TNF)- $\alpha$  antibodies (infliximab, adalimumab or certolizumab) or immunomodulator therapy (methotrexate or azathioprine) also had significant improvements in depressive symptoms (28). Furthermore, Guloksuz et al. (38) reported changes in depression scores in patients with CD at 2, 4 and 8 weeks after an infliximab infusion (see Table 1). In contrast, a paediatric study carried out in the United States failed to show an effect of infliximab infusion on depression scores in children and adolescents with CD (24).

When taken together these studies suggest that the risk of psychological manifestations is increased during the active phase of IBD, however, the results for patients during remission remain unclear. Maconi et al. (32) reported that anxiety/depressive symptoms were present in 36.9% of CD patients in remission and strikingly that 58% of these patients were not currently receiving treatment for psychological illness. Similarly, Knowles et al. (39) reported that of CD patients with anxiety (48%) and depression (42%) only 20% and 31%, respectively, are receiving psychological care. Besharat et al. (44) also reported high rates (32%) of depressive characteristics in a group of Iranian IBD patients and patients with indeterminate colitis, despite all patients being in remission at the time of the study. This observation is echoed in an Australian cohort where despite 74% being in remission 96% had significant disease-related concerns, and symptoms of depression and anxiety were reported by 21% and 40%, respectively (29). In slight contrast to some studies mentioned previously, Iglesias et al. (47) reported that a cohort of CD patients in remission for at least 6 months on infliximab therapy were shown to have increased anxiety and a decreased frequency of depression. This study concluded that despite clinical remission a significant number of CD patients present with anxiety or depressive symptoms, and that those CD patients in remission would benefit from psychological support.

Table 1. Reports of anxiety- and depression-related symptoms in inflammatory bowel disease (IBD) patients

Study	Participants	Measures	Results and author's conclusions
Cawthorpe and Davidson (27): Canada	Adults and children: UC, controls	Medical records: ICD mental disorder and UC	Mental disorder present in 82% of UC sample. Neuroses/depressive disorders are most likely mental disorders to arise before UC diagnosis. Indicates aetiological relationship between mental disorder and UC or between their treatments
Horst et al. (28): USA	Adults: UC, CD	HBI, SCCAI, PHQ-9, CRP	Depressive scores decreased in IBD patients on immunosuppressive therapy. Significant decrease in UC and CD patients at risk of moderate to severe depression. Changes in CRP scores correlate with PHQ-9 (depression) scores
Keeton et al. (29): Australia	Adults: UC, CD	Concerns and worries, HADS, DASS-21	Although 74% of respondents were in remission 96% had significant disease-related concerns, 21% reported symptoms of depression, 40% of anxiety
Kinsinger et al. (30): USA	Adults: UC, CD, other GI disorders	Demographic/psychosocial checklist, BSI, IBS-QOL, medical records	Psychological intervention can reduce healthcare burden for patients with GI conditions and is associated with reduced outpatient visits, medical procedures and medications required
Clark et al. (24): USA	Children and adolescents: CD	CDI, Paris classification, KSADS, PCDAI, ESR, medication use	Infliximab use not associated with decreased depressive symptoms. SES and disease activity were the strongest predictors of depression on the PCDAI
Gandhi et al. (20): USA	Adults: UC, CD	HBI, IBDQ, BDI, PHCS, CISS, CAMBI	Patients with inactive IBD had less depressive symptoms, and improved perceived health competence, task-oriented coping, and QOL compared with those with active IBD
Long et al. (31): USA	Adults ≥65 years: UC, CD	Short-GDS, short-CDAI, SCCAI, short-IBDQ	22.6% of patients had GDS scores consistent with a diagnosis of major depression. Point prevalence of depression did not differ between UC and CD. Depressed patients had significantly higher disease activity scores and decreased QOL
Maconi et al. (32): Italy	Adults: CD-R	CDAI, HADS	Anxiety and/or depressive symptoms were present in 36.9% of patients, 58% of whom were not being treated for anxiety/depression. Anxiety significantly correlated with female sex, history of perianal disease and perianal surgery
Szigethy et al. (33): USA	Children and adolescents: UC-D, CD-D	CDI, KSADS, CDRS-R, IMPACT-III, CGAS, PCDAI, PUCAI	Following 3 months of psychological therapy 65% of all participants no longer met the DSM-IV-TR criteria for depression. IBD activity improved over time for both CBT and SNDT with a slightly larger decrease for CBT
Szigethy et al. (34): USA	Children and adolescents: UC, CD	CDI, CDRS-R, SCARED, IMPACT-III, PCDAI, PUCAI, API, BIPQ, medical records	Greater disease activity in depressed vs. non-depressed youth with IBD. Evidence for three depressive profiles in youth with concurrent IBD and depression
Virta and Kolho (35): Finland	Children and adolescents: UC, CD, controls	Analysis of national drug registers	Significant increase in anti-depressant drug use in IBD youth compared with peers up to 3 years following diagnosis
Vlachos et al. (36): Greece	Adults: UC	CDAI, ZDRS, STAI, HADS	Inducible HSP70 induction in PMN cells of UC patients correlates with depression and anxiety scores in ZDRS, STAI and HADS-D but not HADS-A. This could potentially be a biomarker for depression and anxiety in UC
Ananathkrishnan et al. (37): USA	Adult females: UC, CD, controls	MHI-5	Women with recent depressive symptoms had an increased risk of CD but not UC
Bokemeyer et al. (25): Germany	Adults: UC, CD, IC	CAI, CDAI, PGA, SF-36, IMET-IS	UC and CD patients with active disease more often reported severe depressive symptoms and sexual problems
Guloksuz et al. (38): The Netherlands	Adults: CD	HBI, CDAI, MFI, IBDQ, HAM-D-17, BDI, SCL-90, SCID, APP, zinc, TRP	Anti-TNF-α treatment increased IBDQ scores and reduced SCL-90 depression scores for CD patients independent of disease activity. Depression scores were associated APP-γ over time but not with TRP availability
Knowles et al. (39): Australia	Adults: CD	BIPQ, HADS, SQLS	48% of CD patients had anxiety and 42% depression on the HADS. Of these only 20% and 31%, respectively, were receiving psychological care
Langhorst et al. (40): Germany	Adults: UC	Endoscopy, histology, CAI, PSQ, HADS, CPSS	Short-term stress and male gender but not long-term stress, depression or mucosal healing were predictive of relapse in UC patients
Schuman et al. (41): USA	Adolescents: UC, CD	CDI, FAD, CBCL, LCAI, short-PCDAI	20% of patients scored above the cut-off for depression on the CDI with no difference between UC and CD. Disease severity was a significant predictor of patient-reported but not parent-reported depressive symptoms
Selinger et al. (42): Australia	Adults: UC, CD	Steroid medication self-report, CCKnow, short-IBDQ, HADS	High levels of anxiety (41.8%) and depression (14%) in IBD patients with no difference in anxiety between UC and CD. Anxiety was correlated with level of disease-related knowledge, worse depression scores and lower QOL
Shiga et al. (43): Japan	Adults: UC, CD	Hospital records, Mayo disease scores (UC), HBI	Significant increase in relapse rate observed among UC but not CD patients following Great East Japan Earthquake compared with the same period of time the previous year. Life-event stress is associated with relapse in UC, not CD
Ben Thabet et al. (26): Tunisia	Adults: UC, CD, patient controls	CDAI, HADS, TAS-20	More IBD patients than controls had high HADS-D (22%) and HADS-A (26%) scores. Approximately 73% of high HADS-D and HADS-A scores were within an active disease phase
Besharat et al. (44): Iran	Adults: UC, CD, IC	SCCAI, BDI	Depression was seen in 32% of patients with IBD despite all patients being in remission. A non-significant correlation was observed between SCCAI, BDI, age and BMI
Goodhand et al. (45): UK	All ages: UC, CD, controls	Medical records	IBD patients on anti-depressants had fewer relapses and courses of steroids in the year following anti-depressant treatment compared with the previous year with a decreased number of endoscopies in year 2 compared with year 1
Goodhand et al. (21): UK	Adults: UC, CD, healthy controls	SCCAI, CDAI, HADS, general-PSQ, FC, CRP, endoscopy	Anxiety and depression scores were significantly higher in IBD vs. healthy controls. No differences in mean HADS scores between UC and CD. Active UC was associated with higher HADS scores but not CD

Table 1 (Continued)

Study	Participants	Measures	Results and author's conclusions
Loftus et al. (46): USA	Children: CD, paediatric controls	ICD-9-CM, epidemiology, medical records, prescription medication	The risk of developing an anxiety or depressive disorder following CD diagnosis is greater for CD patients compared with non-CD patients. CD also increases the risk of developing persistent anxiety and depression
Iglesias et al. (47): Spain	Adults: CD-R	CDAI, CRP, ELISA, HADS	Despite clinical remission, 39% of CD patients had anxiety symptoms and 24% had depressive symptoms. Infliximab therapy is the only factor associated with anxiety, however, it is inversely associated with depression
Vidal et al. (48): Spain	Adults: UC-R, CD-R,	SCID, HBI, SCAI	In remission 31.1% of IBD patients had at least one psychiatric disorder. Anxiety (17.9%) and depression (11.6%) were the most prevalent
Addolorato et al. (22): Italy	Adults: UC, CD, other GI disorders	STAI, ZDRS	State anxiety is related to active UC. Trait anxiety is inversely related to CD in remission. UC in remission is inversely related to depression. Most patients who seek medical consultation for GI problems show associated affective disorders
Vidal et al. (49): Spain	Adults: UC, CD	IBDQ, CDAI, HADS, TCI	44.6% scored >8 in HADS-A or HADS-D. Psychological distress and disease activity were predictors of low QOL
Walker et al. (50): Canada	Adults: UC, CD, community controls	CIDI, CPSS, HAQ, PWB, IBDQ	Social anxiety decreased in IBD vs. controls. Increased major depression in IBD vs. controls. Anxiety or mood disorders lead to decreased QOL perception and earlier onset of IBD symptoms
Calvet et al. (23): Spain	Adults: CD, healthy controls	SF-36, HAM-A, HAM-D-17	Decreased SF-36 score and significantly increased HAM-A and HAM-D scores in active disease vs. healthy controls and thiopurinic-induced remission
Janke et al. (51): Germany	Adults: UC, CD	GLS, HRLS, FLZ, HADS, GIBDI	Increased psychiatric illness, medical comorbidity, and disease activity were risk factors of reduced HRLS in CD. Increased disease activity was the only predictive factor in UC patients
Persoons et al. (52): Belgium	Adults: CD	CDAI, PHQ-9, HADS, TAS-20, SSL-I, infliximab, CRP	Major depression in CD is predictive of lower remission rates
Mardini et al. (53): USA	Adults: CD	CDAI, BDI, BAI, BHS, RLC	Depression scores were significantly correlated with disease activity scores at baseline and 8–12 weeks later. Depressive symptom were positively associated with future changes in disease activity
Mittermaier et al. (54): Austria	Adults: UC, CD	BDI, STAI, IBDQ, PSQ, RFIPC	Depression scores significantly correlated with the number of relapses after 12 or 18 months and the time to disease. Anxiety and HRQOL were also related with more frequent relapses during 18 months
Kurina et al. (55): UK	Adults: UC, CD	ORLS medical records	Depression and anxiety preceded UC but not CD more often than expected in control groups. Depression and anxiety were more common following CD diagnosis. UC was followed by anxiety, not depression more often than expected by chance

API, Abdominal Pain Index; APP $\gamma$ , acute phase protein – gamma; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; BHS, Beck Hopelessness Scale; BIPQ, Brief Illness Perception Questionnaire; BSI, Brief Symptom Inventory; CRP, C-reactive protein; CES-D, Center for Epidemiologic Studies-Depression Scale; CBCL, Child Behaviour Checklist; CDI, Children's Depression Inventory; CDRS-R, Children's Depression Rating Scale – Revised; CGAS, Children's Global Assessment Scale; CAI, Clinical Activity Index; CBT, Cognitive Behavioural Therapy; CPSS, Cohen Perceived Stress Scale; CAMBI, Complementary and Alternative Medicine Beliefs Inventory; CIDI, Composite International Diagnostic Interview; CISS, Coping Inventory for Stressful Situations; CCKnow, Crohn's and Colitis Knowledge score; CD/CD-R/-D, Crohn's disease/in remission/with depression; CDAI, Crohn's Disease Activity Index; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision; DASS, Depression Anxiety and Stress Scale; ELISA, enzyme-linked immunosorbent assay; ESR, erythrocyte sedimentation rate; FC, faecal calprotectin; FAD, Family Assessment Device; FLZ, Fragen zur Lebenszufriedenheit – German questionnaire on life satisfaction; GI, gastrointestinal; GLS, General Life Satisfaction; GP, general population; GDS, Geriatric Depression Scale; GIBDI, German Inflammatory Bowel Disease activity Index; HAM-A/-D, Hamilton rating scale for Anxiety/Depression; HBI, Harvey Bradshaw Index; HAQ, Health Anxiety Questionnaire; HRLS, Health-Related Life Satisfaction; HRQOL, Health-Related Quality of Life; HSP70, heat shock protein 70; HADS/HADS-A/HADS-D, Hospital Anxiety and Depression Scale/-Anxiety subscale/-Depression subscale; IBDQ, Illness Behaviour Questionnaire; IF, immunofluorescent; IMET-IS, IMET – Impairments in Sexuality; IC, indeterminate colitis; ICD/ICD-CM, International Classification of Diseases/-Clinical Modification; IBD, inflammatory bowel disease; IBDQ, Inflammatory Bowel Disease Questionnaire; IBS, irritable bowel syndrome; LCAI, Lichtiger Colitis Activity Index; MHI-5, Mental Health Index-5; MFI, Multi-dimensional Fatigue Inventory; ORLS, Oxford Record Linkage Study; PHQ, Patient Health Questionnaire; PCDAI, Paediatric Crohn's Disease Activity Index; PUCAI, Paediatric Ulcerative Colitis Activity Index; PHCS, Perceived Health Competence Scale; PSQ, Perceived Stress Questionnaire; PGA, Physician Global Assessment; PMN, polymorphonuclear cells; PWB, Psychological Well-Being Manifestations Scale; QOL, Quality of Life; RFIPC, Rating Form of IBD Patient Concerns; RLC, Holmes Recent Life Changes; SCARED, Screen for Child Anxiety-Related Disorders; SF, Short-Form Health Survey; SCCAI, Simple Clinical Colitis Activity Index ; SSL-I, Social Support List – Interactions; STAI, State-Trait Anxiety Inventory; SQLS, Stoma Quality of Life Scale; SCID, Structured Clinical Interview for Axis-I DSM-IV Disorders; SNTD, Supportive Non-Direct Therapy; SCL, Symptom Distress Checklist; TAS, Toronto Alexithymia Scale; TRP, tryptophan; UC/UC-R/-D, ulcerative colitis/in remission/with depression; ZDRS, Zung Depression Rating Scale.

Appending number on abbreviations in table, if present, indicates number of items on test

Anxiety/depression in UC versus CD

It is now widely reported that no psychological differences between UC and CD exist (21,26,31, 41,42). A recent study on the effectiveness of

immunosuppressive therapy on depression in IBD reports differences in prevalence of moderate to severe depression depending on IBD diagnosis (51% CD and 18% UC) (28). Furthermore, differences have been reported in the type of anxiety observed



between UC and CD patients (22) and in the risk of psychiatric factors (anxiety and depression) on health-related life satisfaction in CD compared with UC (51) (see Table 1).

### **Impact of psychological symptoms on the development/course of IBD**

GI and psychological pathologies: cause and effect

An important question surrounding comorbidity of psychological symptoms with IBD is how these may be linked and whether one may predispose to the other. Although there has been a substantial amount of literature on the prevalence of depression and anxiety in IBD, less investigation has been carried out into the effect of such symptoms on the development of IBD or on the course of IBD. This may be due to the longitudinal and more protracted nature of this kind of study. Kurina et al. (55) carried out an extensive analysis of general hospital admissions in southern England between 1963 and 1999, to determine whether patients suffering from IBD had a greater rate of developing depression than would be expected by chance, and whether depression or anxiety preceded or succeeded the diagnosis of IBD. Results showed that with both CD and UC there is a greater chance of suffering from depression, but that in UC the depression is usually diagnosed in the year before onset of the disease symptoms, whereas in patients with CD the depression followed the diagnosis of the disease. Therefore, they suggest that the onset of depression in UC might be causally related to UC, a result of living with an undiagnosed bowel condition. For CD they suggest that depression might be a result of the disease symptoms or treatment of the illness. Cawthorpe and Davidson (27) also found that neuroses or depressive disorders were most likely to arise before UC for men and women. They suggest that psychotropic medication used to treat anxiety and depression may play a role in the aetiology of UC. Concerning paediatric literature on this topic, a 2011 study which analysed medical and prescription claims of children with CD and patient controls observed a 74% increased risk of developing an anxiety disorder after CD diagnosis with an increased risk of developing persistent anxiety or depression following diagnosis and a significantly greater likelihood of being prescribed psychotropic medication (46).

Walker et al. (50) investigated the lifetime risk of depression in the Manitoba IBD patient cohort (Canadian IBD cohort), and carried out a long-term analysis of these patients over 12 months. They report a higher lifetime risk of depression and a

possible higher lifetime risk of some anxiety disorders in IBD patients versus a general Canadian population group. In the majority of patients with lifetime anxiety or depression, the psychological disorders preceded the diagnosis of IBD. Contrary to Kurina et al. (55), Ananthakrishnan et al. (37) found that depressive symptoms increase the risk for CD, but not UC, among women. The reasons for the differences in outcome between these studies are unclear. Further research into the potential impact of psychological disorders on the development of IBD is needed.

Risk of relapse and effects of psychological treatment

A small number of studies have investigated the influence of anxiety or depression on the risk of relapse in IBD. In a study of 112 patients with inactive IBD, Vidal et al. (48) reported that neither depression nor anxiety increased the risk of relapse in UC or CD patients. Langhorst et al. (40) also failed to demonstrate a predictive effect of depression on the risk of relapse in patients with UC. This is contradictory to two older studies where BDI scores were predictive of future changes in IBD activity (53,54). In a paediatric study of children and adolescents with IBD, Szigethy et al. (34) reported greater disease activity in depressed compared with non-depressed youth with IBD. Persoons et al. (52) also reported decreased remission rates in patients with a major depressive disorder.

Goodhand et al. (45) have reported improvement in IBD (see Table 1) in patients who have been prescribed anti-depressants, compared with matched patients who did not receive treatment for depression. In another study by Szigethy et al., this group examined the effect of therapy on depressed youth with IBD (33). They found that cognitive behavioural therapy and supportive non-direct therapy caused an improvement in HRQOL and psychosocial functioning, and were associated with an improvement in IBD activity over time (see Table 1). In a recent study concerning psychological intervention for patients with a range of GI disorders, including IBD, functional bowel disorder, dyspepsia and oesophageal symptoms, Kinsinger et al. (30) reported that psychological intervention can reduce healthcare burden (see Table 1). These studies suggest that psychological assessment may help to identify patients at risk of disease exacerbation or decreased rates of remission and may be an effective way to improve HRQOL. Importantly, these factors suggest that treating the psychological symptoms could be beneficial in terms of the overall course and management of IBD.

### Effects of stress on risk of relapse

As well as anxiety and depression, short-term and long-term stress may influence the course of IBD. Evidence to suggest bidirectional communication between the gut and brain is emerging indicating that psychological stress and/or depression has negative implications for normal gut function. It is also hypothesised that stress may be a risk factor for relapse in patients suffering from IBD, although this remains controversial with some studies reporting no effect of stress on development of IBD or increased risk of relapse (49,56). However, Langhorst et al. (40) found that short-term stress, but not long-term stress, was predictive of relapse in UC patients. The impact of life-event stress on UC, but not CD, was highlighted after the Great East Japan Earthquake in 2011 (43). Results from 12 hospitals, found that UC patients activity scores increased significantly in the 2 months following the earthquake. Dietary changes and anxiety regarding family finance were independent predictors of relapse.

### Immunologic mechanisms underlying psychological disturbance in IBD

#### Inflammatory origins of mood disorders

Mounting evidence indicates that inflammation plays a critical role in the pathophysiology of mood disorders. Patients with schizophrenia, major depression and bipolar disorder have been shown to have elevated levels of pro-inflammatory cytokines (57). Reciprocally, many inflammatory conditions including IBD, rheumatoid arthritis, psoriasis, cardiovascular disease and diabetes (58–61) have been linked to a higher risk of mood disorders. Evidence for this link is also found in studies of cancer patients and hepatitis C patients receiving immune-based therapy. These patients display increases in depressive tendencies while receiving interferon or interleukin-2 treatment, which subside once treatment finishes (62,63). Furthermore, both clinical and preclinical studies have shown that the induction of a pro-inflammatory state in otherwise healthy subjects results in poor mood and ‘sickness behaviour’; a behavioural phenotype resembling depression with symptoms including lethargy, anxiety, social withdrawal, anhedonia and anorexia (64–67). Though they share many symptoms and are both thought to have a basis in inflammation sickness behaviour is distinct from clinical depression. Sickness behaviour is evolutionarily intended to confer benefit by allowing for rest and isolation thus conserving energy, enabling an effective inflammatory response and preventing the spread of infection to others. It has been proposed that for clinical

depression to occur there is a transition from sickness behaviour resulting in sensitisation of immune-inflammatory pathways, progressive damage by oxidative and nitrosative stress, and an autoimmune response directed against self-epitopes with the latter processes leading to neural tissue damage and functional and cognitive artefacts over repeated depressive episodes (68). Considering that IBD is a lifelong disorder involving chronic relapsing and remitting inflammation and activation of oxidative and nitrosative pathways (69), it is likely that the depressive behaviour observed in IBD patients is not simply sickness behaviour but a comorbid depression (70). Furthermore, sickness behaviour is evolutionarily intended as an adaptive response to sickness, whereas comorbid depression worsens the original sickness as has been observed in IBD patients (34,52–54), while treatment for depressive symptoms improves IBD course (33,45). In response to the above findings the use of anti-inflammatories as an adjunct to conventional therapy for depression has been explored and suggests a beneficial effect though further research is required in this area (71). Potential mechanisms for the inflammatory induction of behavioural changes may include effects of cytokines on hypothalamic–pituitary–adrenal (HPA) axis dysregulation, monoamines and the kynurenine pathway, over-activation of microglia, impairments in neuroplasticity, and structural and functional changes in the brain.

#### Factors influencing anxiety and depression in IBD

Some socioeconomic/environmental/physiological factors such as education, socioeconomic status, gender, diet, pain, perceived stress, etc. may be predictive of or have an effect on psychological disturbance in IBD and are worth studying to increase our understanding of disease pathogenesis and psychological comorbidity. These factors may account for some of the variation observed across studies of depression and anxiety in IBD and are noted in Table 1 where applicable.

Various studies have observed that lower socioeconomic status and lower educational level are associated with depression and anxiety in IBD patients (41,72,73). Such patients are also shown to have lower HRQOL than the general population, however, it is difficult to draw conclusions from this link as this may be a result of other non-disease-related factors (74).

Generally, there is little difference in IBD occurrence between men and women (75). However, gender does appear to be linked to differences in psychosocial manifestations of the

disease. The majority of studies indicate that female gender is a predictor of anxiety and depression in IBD (32,72,76). Females are also believed to be more susceptible to the impact of IBD on HRQOL (77) potentially due to increased symptom perception in women (78). Females with IBD are also more likely to have IBS-like symptoms concurrent with IBD (79), greater levels of fatigue (80), and show a higher incidence of mood swings among those with CD (81), all of which may impact on HRQOL and psychological health.

Although diet is not a causative factor in IBD it is thought to be a potential trigger for IBD flares, and it is believed that the Westernised diet rich in processed foods is a factor in the increased incidence of the disease in these regions (82). A modified diet limiting excess fat, carbohydrates, fibre and lactose, and encouraging intake of pre- and probiotic foods may be helpful as an adjunct therapy in IBD in decreasing symptoms and reducing medication requirements (83). Although it is still unclear whether dietary modification would be therapeutic in the psychological aspects of IBD, considering the link between diet, stress and the influence of gut microbiota on mood it is reasonable to think that this may be beneficial and will be addressed further later in this review.

The literature indicates that active IBD is associated with an increase in psychological manifestations (24,31) with disease severity being an independent predictor of depressive symptoms (41,76). UC patients with pain have been shown to have significantly higher depression scores than UC patients without pain (84), with higher pain scores being an accurate predictor of depression in both UC and CD (84,85). As well as pain, the nature of other symptoms experienced by IBD patients can be extremely stressful. As will be discussed in greater detail later in this review, stress can affect visceral sensitivity, gut motility and the immune system in IBD, and as previously noted may be a trigger for IBD flares (40). Perceived stress has been associated with mood disturbance in both UC and CD (21) indicating a link between stress, symptom-related or otherwise, and psychological disturbance in IBD.

#### Inflammation and depression in IBD

Despite the recent surge in psychoneuroimmunology research, there is a lack of investigation into the inflammatory mediators and mechanisms underlying psychological disturbances during active IBD. There may be psychoneuroimmunological components that predispose some people to the development

of UC. Vlachos et al. (36) assessed levels of constitutive and inducible heat shock protein 70 (HSP70) at various sites in the colon of UC patients. They found that inducible HSP70 was strongly expressed in polymorphonuclear (PMN) cells in the colonic mucosa of the majority of patients. They also report that the induction of HSP70 significantly correlated with anxiety and depression scores in various psychometric tests, including HADS-D, STAI and Zung Depression Rating Scale, and with the Rachmilewitz Clinical Activity Index but not with HADS-A scores. This group suggest HSP70 induction in PMN cells as a possible biomarker for depression and anxiety in UC.

In addition to clinical investigations, experimental models of IBD in animals allow for the study of interactions between the gut and the brain during and in recovery from colitis in order to decipher the mechanisms by which IBD interacts with the central nervous system (CNS) and to develop potential therapies to best manage comorbid symptoms. Due to the paucity of biomarkers (molecular and cellular) reported in human studies, arising from the difficulty in assessing impact of stress and/or psychological disturbance in IBD in a clinical setting, data available from animal models are the best available source to obtain insight into gut–brain interactions underlying comorbidity in IBD.

#### Animal models of IBD

As the exact aetiology of IBD is still largely unknown there are many possible factors which contribute to different aspects of the pathophysiology of the disease including immune system dysfunction, dysregulation of the microbiota, genetics, inflammation and oxidative stress. Animal models of IBD have been developed to allow for investigation of aetiological factors in terms of understanding the mechanisms of disease pathogenesis and developing therapeutic strategies for intervention. These models may be grouped into chemical- or microbial-induced models; spontaneous models; genetically engineered or transgenic models; and adoptive transfer (T-cell) models [for review see (86)].

Despite the range of models of IBD, the main body of behavioural and brain research has been carried out in the chemically induced models, particularly the dextran sulphate sodium (DSS) and trinitrobenzenesulphonic acid (TNBS) models. Okayasu et al. (87) were the first to describe the DSS-induced colitis model which involves oral administration of DSS in the drinking water of the animals leading to the development of acute and chronic colitis. Gaudio et al. (88) assessed the



structural, ultrastructural, immunohistochemical and clinical aspects of DSS colitis in Sprague-Dawley rats in both acute and chronic DSS-induced colitis and suggest that the DSS model is more representative of UC than CD. Indeed, DSS-induced colitis is histologically characterised by infiltration of inflammatory cells, crypt loss and extensive mucosal erosions, with predominance in the distal portion of the large intestine. Occasionally, crypt abscesses and regenerated epithelium are also seen. The TNBS model of colitis was first reported by Morris et al. (89). This model of IBD involves a single enema of the toxin TNBS in an ethanol solution. TNBS-induced colitis results in a T-cell (TH1)-mediated inflammatory response which is described as CD-like in nature (90). Unlike the DSS model which predominantly involves the distal colon, TNBS can induce a more widespread colitis, involving macroscopic ulceration of the large intestine with varying severity, strictures of the lumen and fistulae formation. Both of these models result in immune activation in the gut, are histologically representative of IBD, and despite their limitations in terms of studying disease aetiology are valuable tools for studying mechanisms of IBD pathogenesis. Both models are simple, inexpensive, reproducible and valid for examining the potential interaction between intestinal immune activation and the CNS.

Other animal models used to investigate the association between GI disturbance and psychological manifestations include infection models by which bacteria such as *Citrobacter rodentium* and *Campylobacter jejuni*, which colonise and disrupt tissue in the GI tract of mice and are effective models of acute colitis. *C. rodentium* uses attaching and effacing lesions to colonise the GI tract resulting in ulcerative intestinal lesions, reduced barrier integrity, production of pro-inflammatory cytokines and manifesting as weight loss and diarrhoea (91). *C. jejuni* produces and secretes toxins to aid in its intestinal colonisation and increase mucosal barrier damage, translocation of commensal bacteria across the intestinal epithelium and induction of a Th1 immune response (92). Stress-induced models may be used to study the effects of psychological stress on GI function. Maternal separation as a model of early life stress (93), chronic subordinate colony housing (94,95) and overcrowding stress (96) have been shown to induce spontaneous GI dysfunction or to increase susceptibility to chemically induced colitis. Though not wholly valid for studies on IBD specifically these models demonstrate the link between stress and GI disturbance and are functional tools in assessing IBS-like symptoms.

CNS disturbances in models of IBD

*Anxiety-/depression-like behavioural alterations.* In a recent study, Heydarpour et al. (97) show an increase in immobility in the forced swimming test (FST), a depression-related behaviour in mice 3 days post-TNBS injection. This effect is attenuated using a specific inducible nitric oxide synthase (iNOS) inhibitor (aminoguanidine) administered 30 min before the FST indicating the potential involvement of the nitric oxide pathway in the induction of this behaviour. In the DSS model of colitis, Chen et al. (98) performed anxiety and depression-related behavioural tests in rats following a DSS (5%) colitis induction period and reported that DSS exposure caused a decrease in open arm entries and time spent in the open arm of the elevated plus maze (EPM) indicating anxiety, with an increase in immobility time in the FST indicating learned helplessness. DSS exposure also decreased sucrose preference in the sucrose preference test indicating reduced responsivity to a rewarding stimulus, anhedonic behaviour symptomatic of depression, and reduced social interaction between animals suggestive of social avoidance and withdrawal. Interestingly, this study also found that the anxious- and depressive-like behaviours were reversed by prolonged desensitisation of transient receptor potential vanilloid 1 (TRPV1)-expressing colonic afferent neurons using a colonic infusion of the potent analogue of capsaicin and activator of TRPV1, resiniferatoxin. In an earlier study, Messaoudi et al. (99) analysed lever pushing behaviour in an aversive light stimulus avoidance test in rats exposed to TNBS. They found that colitic rats had a lower number of total active lever pressings and did not discriminate the active lever from the inactive one. This behavioural disturbance was attributed to TNBS-induced pain as morphine returned lever pressing to control levels. Despite not being suggestive of depression or anxiety this highlights the importance of accounting for the potential influence of pain on behavioural disturbances in these animal models. Painsipp et al. (100) analysed female and male mouse behaviour in the EPM, open field (OF) and FST on days 8, 9 and 11, respectively, of an 11 day DSS (2%) exposure protocol. Colitis had some behaviour modulating effects which were sex dependant: male mice spent significantly less time in the open arms of the EPM indicative of anxiety-like behaviour, whereas female rats had increased immobility in the FST indicative of a depressive-like phenotype. Lyte et al. (101) examined anxiety-like behaviour on a hole-board OF apparatus in mice infected with *C. rodentium*, a murine model of IBD. Male mice were tested 7–8 h post-infection and results provide evidence for an anxiety-like phenotype: decreased exploration of the

inner zone of the OF, decreased number of pokes into the holes as well as a preference for the first corner hole compared with control mice. A more recent study using the same colitis mouse model assessed anxiety-like behaviours in the light/dark box and found no behavioural alterations at 10 days post-infection when inflammation was at its peak (102). However, Emge et al. (103) using a DSS colitis model, reported that during active inflammation (8 days post-DSS) mice exhibited anxiety-like behaviour in the light/dark box, whereas recognition memory was impaired in the novel object recognition test. These behavioural alterations had normalised by 14 days post-DSS when the colitis had resolved. In an investigation by Bercik et al. (104) mice who received 3% DSS in drinking water during three 1-week cycles demonstrated increased anxiety in the step-down test compared with controls.

*Sickness behaviour versus depressive-like behaviour.* Considering the moderate physiological effects of chemically induced and infection-induced colitis the validity of behavioural tests, particularly those which passively measure depressive-like behaviour during acute sickness should be questioned. In behavioural tests such as OF and FST where lack of activity may be interpreted as anxiety- or depressive-like behaviour one should not discount the impact of abdominal pain being experienced by animals with active colitis. Diarrhoeal symptoms associated with colitis may affect grooming behaviour and may also impact social interaction tests. Few studies, if any, report disease activity scores or take disease activity into account in behavioural tests of colitic animals with many studies also not reporting the timepoint during colitis at which each behavioural test was carried out. In a study of lipopolysaccharide (LPS)-induced alterations in Fos expression in the brain Frenois et al. (105) argue that there is a functional difference in cytokine-induced sickness behaviour observed when LPS-sickness is at its peak (decreased motor activity 6h post-LPS i.p. injection) and the cytokine-induced depressive-like behaviour observed (increased immobility in FST at 24h and decreased sucrose preference at 24 and 48h post-LPS) when LPS-induced sickness was minimal (and motor activity and food/fluid intake had returned to normal). At 24 and 48h post-LPS increased cellular activity was measured by Fos labelling in brain structures including the amygdala, hippocampus and hypothalamus, however, at 6h post-LPS no Fos labelling was observed in these regions. This points to an underlying difference in sickness behaviour and depressive-like behaviour induced by a systemic inflammatory insult.

It would therefore be of interest to measure behavioural abnormalities in animal models of colitis during the recovery period when IBD-like symptoms have ceased.

*Blood brain barrier (BBB) permeability.* The BBB is a tightly controlled diffusion barrier which regulates the transport of molecules between the periphery and CNS. Endothelial cells of the BBB are non-fenestrated and have more extensive tight junctions acting as a protective barrier against pathogens and neurotoxic substances, whereas allowing influx of essential nutrients and neurotransmitters (106). Systemic inflammation can disrupt the BBB and has been linked to syndromes such as sickness behaviour and delirium, and neurological disorders such as Alzheimer's disease and multiple sclerosis (107). The presence of intestinal inflammation in IBD models and the increase in permeability of the gut-blood barrier has been linked to an increase in the permeability of the BBB. Hathaway et al. (108) investigated potential disruption to the BBB in rabbits exposed to TNBS. Barrier disruption was assessed following i.v. administration of low molecular weight fluorescein (MW 376 Da) or a higher molecular weight molecule fluorescein isothiocyanate (FITC)-dextran (MW 71 000 Da) 48h post-TNBS administration. Results demonstrated a significant increase in the permeability of the BBB to fluorescein, however, no difference in permeability to the higher molecular weight FITC-dextran was found. In a later investigation they confirmed these findings and suggest that free radical damage is not responsible for the BBB disruption (109). More recently, Natah et al. (110) further analysed the BBB disruption in Sprague-Dawley rats exposed to TNBS to determine the anatomical sites of the BBB disruption using sodium fluorescein (MW 376 Da) or IgG (MW 156 000 Da) as a marker of increased permeability. As per Hathaway et al. (62,63) they revealed an increased permeability to the low molecular weight sodium fluorescein but not to the larger IgG molecules. The regions of higher permeability were located at the circumventricular organs: specifically the organum vasculosum of the lamina terminalis, subfornical organ and median eminence during days 1 and 2 following TNBS administration.

Sans et al. (111) measured expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) using a dual radiolabelled antibody technique in four different colitis models: IL-10<sup>-/-</sup> mice, Structured Clinical Interview for Axis-I DSM-IV Disorders mice reconstituted with CD45RB<sup>high</sup> T-cells, mice with DSS-induced colitis

and rats with TNBS-induced colitis. VCAM and ICAM are endothelial CAMs of the immunoglobulin super family which are responsible for the adhesion of leucocytes in various inflammatory diseases. This study demonstrated that there is a significant increase in VCAM expression in the brain of all four models of colitis, which corresponded with colonic VCAM expression and colon weight. They also report that TNBS-induced colitis induces ICAM expression, although this is not the case in the DSS model. These changes were not associated with increased leucocyte infiltration to the brain and are not representative of BBB disruption, however, they provide further evidence of molecular alterations at the BBB following colonic inflammation.

The consequences of BBB disruption in inflammatory conditions such as IBD is that it leaves the CNS vulnerable to inflammatory mediators and gut-derived bacterial or viral antigens. In the case of IBD these inflammatory mediators are likely to be at higher concentrations in the circulation considering the increased permeability of the intestinal barrier in this condition.

*Inflammatory mediators in the brain.* Cytokines are soluble, regulatory proteins, released by immune cells, which act as intercellular mediators. They also have the ability to interact with the CNS either via the vagus nerve or by directly interacting with the BBB, thus providing a means of communication between the immune system and the brain. Cytokines are implicated in the pathogenesis of IBD, with a pivotal role in regulating intestinal inflammation and the clinical symptoms of IBD (112). The use of TNF- $\alpha$  antagonists as a standard therapy for IBD highlights the crucial role of cytokines in this disease. Following peripheral immune activation cytokines can also be produced within neurons and glial cells in the brain and their involvement has been proposed in the pathophysiology of a number of psychiatric disorders including depression (113) as discussed in a previous section.

*TNBS model.* Riazi et al. (114) investigated the influence of TNBS-induced colitis on hippocampal TNF- $\alpha$  concentrations and microglial activation in male Sprague-Dawley rats. They found an increase in both hippocampal TNF- $\alpha$  protein concentrations and microglial activation at 4 days post-TNBS administration, both of which had returned to basal concentrations at day 10. In a later study Medhi et al. (115) confirmed that a single enema of TNBS induces increases in circulating TNF- $\alpha$  concentrations which are paralleled by increased brain TNF- $\alpha$  protein concentrations. However, unlike the Riazi et al. (114) study the increase was

still present at day 15 post-TNBS administration possibly due to differences in the strain of rat used (115). Wang et al. (116) investigated the effect of TNBS-induced colitis on IL-6 expression in the brains of female Wistar rats at 3, 7, 14, 21 and 28 days post-enema. They report an increase in IL-6 messenger RNA (mRNA) expression and IL-6 protein concentration in the hypothalamus and cerebral cortex, which peaks at 7 days post-enema. Concentrations of brain IL-6 were also increased in mice exposed to TNBS, however, peak IL-6 concentrations were at 2 days post-enema and remained increased 7 and 15 days post-TNBS administration (117). In their study they also report a decrease in the concentrations of the anti-inflammatory cytokine IL-10 at 2 and 7 days post-TNBS. Alhouayek et al. (118) also reported increased central inflammatory cytokine expression following TNBS-induced colitis. Three days post-TNBS administration there was an increase in IL-1 $\beta$ , TNF- $\alpha$  and monocyte chemoattractant protein 1 mRNA expression in the brains of C57BL/6 mice, which was associated with an increase in circulating endotoxin concentrations attributable to extensive histological damage to the colon.

*DSS model.* Villaran et al. (119) reported a significant increase in TNF- $\alpha$ , IL-6, IL-1 $\beta$  and iNOS mRNA expression in the substantia nigra of male Wistar rats during acute DSS-induced colonic inflammation. More recently, Reichmann et al. (120) measured levels of IL-1 $\beta$ , IL-6, IL-17A, IL-18, TNF- $\alpha$  and growth-regulated oncogene (GRO)- $\alpha$  in the circulation and in the hypothalamus, hippocampus and amygdala of mice following 7 days DSS administration (2%) and in combination with water-avoidance stress (WAS). A prolonged immobility in C57BL/6N mice with DSS-induced colitis during WAS was associated with brain region-dependent alterations in the expression genes associated with energy homeostasis [neuropeptide-Y (NPY), NPY receptor Y1], stress pathway activation [corticotropin-releasing factor (CRF), CRF1 receptor and glucocorticoid receptor] and neurogenesis (brain-derived neurotrophic factor). They report increased GRO- $\alpha$  in the hypothalamus as a result of DSS alone. The combination of DSS and WAS induced increases in IL-6 in all three brain regions and in GRO- $\alpha$  in the hippocampus and hypothalamus. Cytokine concentrations in the brain did not correlate with plasma cytokine levels suggesting that WAS is required to effect a brain inflammatory response in DSS-exposed mice. The authors propose that alterations in gut-brain signalling may be responsible for the observed behavioural changes in response to

stress in DSS animals. As well as demonstrating a decrease in hippocampal neurogenesis in DSS (3%)-treated mice Zonis et al. (169) also show an increase in circulating IL-6 and an increase in hippocampal IBA1 and GFAP, markers for activated microglia and astrocytes, respectively, in acute colitis. Following three more rounds of DSS increases were observed in hippocampal TNF- $\alpha$ , IL-1 $\beta$  and GFAP mRNA expression and IBA1 and IL-6 protein simultaneous to the reductions in neurogenesis.

*Effects of cytokines on the brain.* Apart from their primary role in the inflammatory immune response cytokines have the ability to interact with the brain. Cytokine receptors located on the BBB allow for non-barrier-disruptive communication between the periphery and brain though in some cases cytokines may actually cross the BBB either via transporters or via a compromised BBB (107). Diapedesis of leucocytes across the BBB may also lead to immune activation and cytokine production in the brain (121). Microglia can respond to these cytokine signals in paracrine and autocrine fashion to facilitate tissue repair, initiate immune responses and recruit immune cells, however, sustained activation of microglia can result in neurotoxicity and production of reactive oxygen species (122). Astrocytes also communicate using the cytokine network to influence immune responses in the CNS and there is also evidence to suggest that activation of astrocytes by inflammatory mediators modulates astrocyte signalling thereby influencing synaptic and neural function and potentially playing a role in the behavioural effects of inflammation such as sickness behaviour and depression (123). Cytokines can directly affect neuronal activity, influencing neuronal excitability neuronal plasticity, neuronal development and synaptogenesis (124–126). Cytokines have been shown to affect neurotransmitter metabolism, specifically glutamate, serotonin and dopamine, in brain regions associated with emotional regulation namely the nucleus accumbens, amygdala and hippocampus (127). Cytokines can also affect the kynurenine pathway in the brain by stimulating indoleamine 2,3-dioxygenase (IDO) production. As the IDO enzyme is responsible for conversion of tryptophan to kynurenine the amount of tryptophan available for serotonin production is decreased and depressive-like behaviour is observed (128). Pro-inflammatory cytokines may also increase kynurenine-3-monooxygenase enzyme activity. This enzyme degrades kynurenine into 3-hydroxykynurenine, shifting the kynurenine pathway from neuroprotection towards neurotoxicity with the production of neurotoxic metabolites and excitotoxicity. Cytokines can also

influence the HPA axis impacting glucocorticoid receptor function, HPA feedback regulation and causing activation of the HPA axis (129,130). HPA axis activation results in an increase in glucocorticoids which has been implicated in depression (131). [For a more detailed review of the role of pro-inflammatory cytokines in neuro-inflammation and depression see Kim et al. (132).]

#### Regional patterns of neuronal activation

c-Fos is an immediate-early gene expressed following an action potential which is used to indirectly measure neuronal activity [for reviews see (133,134)]. Original evidence of c-Fos activation in the nervous system following induction of colitis was published by Miampamba and Sharkey (135). Colitis was induced following a per-endoscopic injection of formalin and rats were euthanised 2 h later. Immunohistochemical analysis demonstrated a significant increase in c-Fos in the lumbosacral spinal cord, and in two circumventricular organs: nucleus of the solitary tract (NST) and area postrema. Treatment with the  $\alpha$ -2-adrenoceptor agonist xylazine inhibited the colitis-related increase in regional c-Fos expression. A later study by Porcher et al. (136) extensively analysed the expression of c-Fos 2 h post-TNBS administration throughout the brain. They report significant increases in c-Fos immunostaining across a number of brain regions including brain nuclei involved in the autonomic, behavioural and neuro-endocrine response to inflammation, in most circumventricular organs and in CRF pathways particularly the paraventricular nucleus (PVN) of the hypothalamus. At 6 h post-TNBS administration c-Fos mRNA expression in the PVN had completely returned to basal levels. Welch et al. (138,139) focussed on TNBS-induced c-Fos activation in a number of brain regions which are abnormal in autism spectrum disorder (ASD); periventricular grey, hypothalamic/visceral thalamic stress axes and cortical domains, and septal/preoptic/amygdalar brain areas. ASD is a complex, multifaceted neurodevelopmental disorder which is often linked to GI disturbance (137). Results from this study support previous evidence of increased c-Fos induction following experimentally induced colitis, however, here the results suggest prolonged neuronal activation (138). In a later study, this group showed that subdiaphragmatic vagotomy did not inhibit the observed increase in c-Fos induction in the PVN of the hypothalamus, basolateral amygdala, central amygdala (CeA), and piriform cortex indicating the unlikely role of the vagus nerve in mediating the brain activation response in these regions (139).



However, a separate study which used *C. jejuni* infection to induce intestinal inflammation in mice showed c-Fos induction in vagal sensory ganglia and in the NST – the primary sensory vagal afferent nucleus indicating that intestinal inflammation signals to the brain via this nerve (140).

### The microbiota–gut–brain axis

Clinical IBD, gut microbiota and therapies

In terms of gut–brain axis research, the gut microbiota and its associations with brain and behaviour is currently one of the most promising areas of study. The gut microbiota comprises the largest collection of microorganisms in the body, existing in a symbiotic relationship with the host and in the colon reaching a concentration of  $10^{11}$  or  $10^{12}$  cells/g of luminal contents (141). Collectively, the human gut microbiota is thought to be composed of between 15 000 and 36 000 bacterial species (142). The major bacterial phyla found in the gut are *Firmicutes* and *Bacteroidetes* though other phyla including *Actinobacteria*, and *Verrucomicrobia* are also present (143). The gut microbiota is believed to play a role in the pathogenesis of IBD. Dysbiosis of the commensal gut bacteria is commonly observed in IBD, generally as a decrease in diversity of *Firmicutes* and an increase in *Proteobacteria* (142), furthermore, many of the susceptibility genes for IBD are related to microbial recognition and processing (144), and antibiotics are known to be effective in reducing IBD symptoms (145). This is also supported by the finding that germ-free (GF) mice do not develop severe colitis (146).

A strong link has been discovered between a healthy gut microbiota and satisfactory CNS functioning. The microbiota has been implicated in several neuropsychiatric disorders including depression, anxiety, autism and schizophrenia [for review see (147)]. The bacterial flora of the gut can communicate with the brain via vagal pathways and immune mediators as previously discussed, as well as by the production of microbial metabolites. In a healthy individual this bidirectional communication maintains host homeostasis, whereas for an IBD patient, for example, this balance is disturbed with potential consequences for the CNS.

The imbalance observed in the gut microbiota of IBD patients presents a potential therapeutic target. Manipulation of the gut microbial flora can be achieved using probiotics, prebiotics or a combination of both (synbiotics). A probiotic a live microbial food supplement that beneficially affects the host by improving its intestinal microbial balance (148). A prebiotic is a non-digestible food ingredient

that beneficially affects the host by selectively stimulating the growth, activity, or both of one or a limited number of bacterial species already resident in the colon (149). Faecal microbiota transplantation (FMT), an extremely effective treatment for *Clostridium difficile* infection, is another method of gut microbiota manipulation being explored as a potential therapy for IBD patients. The procedure involves transplant of a faecal preparation from a healthy donor into the colon of the patient via naso-enteric tube, colonic enema or in capsule form. In *C. difficile* infection this works by restoring balance to the gut microbial environment. Although IBD is a more complicated condition with many genetic, environmental and immune factors at play, the restoration of a healthy gut microbiota would likely be advantageous at least for some patients.

Effects of microbiota modulation on IBD and brain function

To date, clinical studies investigating the effects of probiotics or prebiotics in IBD have focussed on the physiological symptoms of IBD itself. Probiotics (a preparation of live, beneficial bacteria) show efficacy in inducing remission and increasing remission times in UC (150), which was not the case in CD (151). Despite promising results in TNBS and DSS colitis, prebiotics (preparations of dietary nutrients which support the growth of beneficial host bacteria) have been tested in few clinical trials. Similar to probiotics, results show efficacy in reducing inflammation and inducing remission in UC (152–154), whereas somewhat controversially reducing disease activity and inflammation in CD (155,156). Although no work has explored the potential therapeutic benefit for probiotics or prebiotics in reducing anxiety/depression specifically in IBD patients, this therapeutic strategy has been tested in other cohorts. Messaoudi et al. (157) administered a probiotic mixture of *Bifidobacterium longum* and *Lactobacillus helveticus* for 30 days to both rats and healthy human volunteers and showed a decrease in anxiety-like behaviour in rats and a decrease in anxiety and depression scores in humans in the HADS and Hopkins Symptom Checklist (HSCL-90). Similarly Rao et al. (158) administered a strain of *Lactobacillus casei* to chronic fatigue patients resulting in a reduction in anxiety scores. In terms of prebiotics (159) administered a 3 week course of galactooligosaccharide (GOS) or fructo-oligosaccharide (FOS) prebiotic to healthy controls. The GOS resulted in a decrease in waking cortisol levels and decreased attentional vigilance to negative versus positive emotional stimuli compared with placebo. FOS had no effects in either test. Considering these encouraging

data, the use of microbiota modulation by pre/probiotics as a simple, non-invasive therapy for the psychological as well as physiological effects of UC and potentially CD is an area which should be further explored in future. In terms of FMT as a treatment for IBD, a systematic review of the literature from case reports and cohort studies showed a modest increase in remission rates in IBD patients receiving FMT therapy (160). More recently, two randomised, controlled trials have been carried out in UC patients with conflicting results suggesting a beneficial outcome that may be dependent on donor stool, route of administration, dosage, time since diagnosis and whether patients are also receiving immunosuppressive therapy (161,162). Interestingly, Irish researchers have recently postulated that FMT may be of therapeutic benefit in depression after showing that FMT from depressed human patients into microbiota-deficient rats induces a depressive phenotype in the rats with symptoms of anhedonia and anxiety (163).

#### Animal models of IBD and the gut microbiota

In animal studies the modulation of the microbiota has been used to alter behaviour. GF mice display decreased anxiety-like symptoms in the EPM, OF and light/dark box compared with specific-pathogen-free mice (164). GI microbial infection and inflammation, including exposure to DSS-induced colitis, results in an increased anxiety-like profile (101,165,166). Modulation of the gut microbiota using probiotics can alter the behavioural response. Anxiety and/or depression-related behaviours in the EPM and FST in Balb/c mice (167) and in the FST in maternally separated rats (168) are rescued by probiotics. Probiotics also reduce anxiety-like behaviours induced in rats in response to DSS colitis (165). This points to a potential therapy for neuropsychiatric disturbance in IBD patients. In an aforementioned study by Bercik et al. (104) results demonstrated that increased anxiety measured in the step-down test observed in DSS colitis mice was reversed by the probiotic *B. longum* NCC3001 without affecting gut inflammation (as measured by myeloperoxidase activity and histological scores). They found that the anxiolytic effect of *B. longum* was lost in mice vagotomised before the third cycle of DSS potentially due to the modulatory effects of the fermentation products of *B. longum* on enteric neuron excitability. In another previously mentioned behavioural study Emge et al. (103) reported that the deficits in recognition memory and anxiety-like behaviour during active inflammation on day 8 post-DSS were ameliorated by administration of a probiotic mixture containing *Lactobacillus*

*rhamnosus* and *Lactobacillus helveticus* (103). This study also observed a significant decrease in c-Fos expression in the CA1 region of the hippocampus in mice at day 8 post-DSS which is similarly rescued by administration of the *L. rhamnosus* and *L. helveticus* probiotic combination. It has recently been observed that intestinal inflammation may impact upon hippocampal neurogenesis (169). Following four cycles of DSS (3%) in mice Zonis et al. (169) observed a downregulation in markers for stem/early progenitor cells, with a concomitant increase in p21, a suppressor of cell proliferation, indicating a reduction in neurogenesis in the hippocampus. As p21 can be stimulated directly by pro-inflammatory cytokines it has been proposed that this decrease in hippocampal neurogenesis may occur as a consequence of the increase in activated microglia and astrocytes observed in the hippocampus at the acute phase of colitis and in chronic colitis, respectively.

#### Influence of psychological stress on healthy gut function

The HPA axis represents a major axis of the neuroendocrine system that controls reactions to stress. Dysregulation of the HPA axis has been linked to a number of mood disorders including depression, anxiety and bipolar disorder. The HPA axis is regulated by CRF which is released centrally from the hypothalamus or peripherally from the adrenal cortex in response to stress. Central CRF promotes HPA axis activity via the adrenocorticotrophic hormone (ACTH) – glucocorticoid system and peripheral CRF directly influences stress-induced alterations in gut motility.

#### Effects of stress on the gut

Konturek et al. (170) describes a number of stress-induced disturbances to normal GI physiology: including alterations to GI motility, GI secretion, GI mucosa and mucosal blood flow, intestinal microbiota and also increased visceral perception and intestinal permeability. Deng et al. (171) recently showed that levels of colonic cytokines (IL-6, IL-1 $\beta$  and IL-17A) and neutrophil infiltration in DSS-exposed rats are further increased by chronic unpredictable stress. Previous investigations have shown that when chronically stressed, animals can develop spontaneous inflammation in the bowel (94,172). Reber et al. (94) examined the effect of chronic psychosocial stress on histological changes in the murine colon. Their results demonstrate that exposure to chronic subordinate colony housing leads to colonic inflammation resulting in macroscopic damage to the mucosal layers of the colon,

and an increased secretion of pro- and anti-inflammatory markers by the mesenteric lymph node.

Milde and Murison (173) report decreased time to symptom expression in DSS rats previously exposed to restraint stress, and in a separate study involving electric shock pre-DSS exposure they report a sensitising effect of stress on later vulnerability to intestinal permeability (174). The genotoxic agent azoxymethane predisposes mice to develop CRC when challenged with DSS. Peters et al. (175) report increased risk of inflammation-related CRC when azoxymethane mice were also exposed to chronic subordinate colony housing. Review of maternal separation has also reported disturbances to gut function as a result of early life stress (93). These maternally separated rodents can be used as a model of IBS due to their IBS-like functional symptoms, they are also reported to have altered neurotransmitter activity in the enteric nervous system, GI immune dysregulation, increased intestinal permeability and disturbed intestinal microbiota. One caveat when studying the effect of psychological stress or maternal separation on models of colitis is that both result in increased permeability of the intestinal tract, therefore any enhanced colitic effect may be due to increased permeability to the DSS or TNBS themselves rather than due to altered immune activation, bacterial translocation or neuroendocrine function.

### GI effects on the HPA axis

Due to the bidirectionality of the gut–brain axis not only will a disturbance such as stress influence the GI system but a disturbance in the GI system may also influence stress by activation of the HPA axis. In the Reichmann et al. (73) study DSS treatment increased basal and post-stress (90 min) levels of circulating corticosterone – an index for increased HPA axis activity. Greenwood-Van Meerveld et al. (176) studied the long-term effects of acute colitis on the expression of central CRF in rats. They found a significant increase in CRF mRNA expression in the PVN of the hypothalamus 3 days post-TNBS administration, which persisted up to 30 days post-TNBS. The increased CRF expression was also present in the CeA 3 days post-TNBS administration, however, it had returned to basal levels in this region 30 days post-TNBS. Porcher et al. (136) reported increased expression of the CRF1 receptor mRNA expression in the PVN following TNBS-induced colitis, however, unlike CRF the CRF1 receptor mRNA levels had returned to baseline within 12 h of TNBS administration. Kojima et al. (177) report the opposite effect: decreased CRF expression in the


PVN at 3 and 7 days post-TNBS administration. They do, however, report increased circulating corticosterone on days 1, 3, 7 and 14 post-TNBS. Both studies were carried out in male Sprague-Dawley rats, however, the doses of TNBS were much lower in the Kojima et al. (177) study indicating that a higher dose of TNBS may provoke a more severe colitis necessary for increased CRF expression in the brain.

### Clinical neuroimaging studies

In the clinical literature, information on the effects of IBD on brain structure and function are limited to neuroimaging studies, of which there are very few. A 2011 neuroimaging study investigating the response of UC sufferers to emotional stimuli strongly indicated that IBD could potentially cause psychological disturbances by altering function of brain regions. Functional MRI, using blood oxygen level detection imaging of UC patients 6 months in remission demonstrated a decreased sensitivity to positive stimuli (178). Due to the subjects being in remission, this study is a strong indicator that IBD can cause persistent psychological alterations in patients. An MRI study conducted by this group in 2013 found that IBD affects grey matter volume and brain size, when CD patients showed decreased grey matter volume in the frontal cortex and anterior midcingulate cortex. In addition, the study showed that this morphological change occurred in a manner that suggested disease duration was negatively correlated to grey matter volume (179) (Fig. 1).

The mechanisms summarised illustrate the bidirectional communication axes between the brain and gut showing how behavioural changes mediated centrally may occur following experimentally induced colitis in rodents and also how stress or alterations in mood states may impact the GI system and result in GI dysfunction and IBD symptoms.

Stress leads to production of CRF from the hypothalamus which acts on the pituitary gland causing it to produce ACTH. This acts on the adrenal gland leading to production of cortisol which then enters into circulation and directly influences the gut. Direct innervation of the gut via the vagus nerve (containing mostly afferent sensory fibres and 10–20% motor and parasympathetic efferent fibres) allows feedback from the gut to the brain and central modulation of the gut. The release of neurotransmitters by the nervous system may influence gut physiology or directly influence the gut microbiota, whereas neurotransmitters produced by enteroendocrine cells in the gut or released as microbial products (short-chain fatty acid, serotonin,



*Fig. 1.* Summary of disturbances to the gut–brain axis when (1) exposed to psychological stress (brain–gut) or (2) animals exposed to experimentally induced colitis (gut–brain). (1) Exposure to psychological stress, anxiety or depression can result in altered gastrointestinal (GI) motility, increased visceral perception, altered GI secretion, increased intestinal permeability, altered intestinal microbiota and altered GI mucosa and mucosal blood flow. (2) Induction of inflammation in the bowel results in symptoms of inflammatory bowel disease (IBD) accompanied by altered blood brain barrier (BBB) permeability with activation of a central inflammatory response (A), increased regional brain activation (B) and activation of the hypothalamic–pituitary–adrenal (HPA) axis (C) in rats exposed to dextran sulphate sodium (DSS) or 2,4,6 trinitrobenzenesulphonic acid (TNBS). Animals with colitis have been reported to develop behaviour indicative of an anxiety- and/depression-related phenotype when compared with non-colitic animals. 5-HT, serotonin; ACTH, adrenocorticotropic hormone; CNS, central nervous system; CRF, corticotrophin releasing factor; CVO, circumventricular organ; EEC, enteroendocrine cell; ICAM, intercellular adhesion molecule; SCFA, short-chain fatty acid; VCAM, vascular cell adhesion molecule.



gamma amino butyric acid) may in turn signal to the neural network. Increased GI permeability allows microbial products and potentially microbes themselves to infiltrate into the circulatory system, and to interact with the immune system and nervous system. Immune system activation leads to the production of cytokines which may enter the circulation or act upon the nervous system. As the circulation reaches the brain these mediators may impact on BBB permeability or initiate inflammatory pathways in the brain including activation of microglia and astrocytes.

### Future directions

Despite a substantial increase in the number of studies investigating the association between IBD and psychological comorbidities in recent years, there has been a distinct lack of investigation into the cause of increased psychological disturbances in IBD. It is possible that the psychological impact of the GI symptoms could be sufficient to induce depression or anxiety. However, it is also likely that inflammatory mediators themselves could be responsible for altered mood or anxiety.

Further attention to specific circulating mediators should be investigated in relation to psychological changes in patients with IBD. This would be beneficial as standard anti-depressants may not be as efficient in minimising the depressive symptoms if inflammatory mediators are responsible for the psychological changes. It is possible that a combination of immunomodulators/anti-inflammatories and conventional anti-depressant therapy, or complementary psychological management techniques may be the most appropriate treatment approach. Encouraging progress in the area of microbiota–gut–brain axis-based therapies also points to potential treatment options.

As no single animal model can fully reflect the true nature of human IBD, further research using existing models and the development of novel models for the disease will contribute to our understanding of the underlying mechanisms of how IBD interacts with the CNS.

### Concluding remarks

Overall, there is a general consensus that IBD is associated with increased vulnerability to depression and anxiety symptoms compared with healthy controls particularly during active disease. Recent evidence has shown that treating psychological symptoms improves HRQOL and reduces the rate of relapse in IBD patients. These results suggest that patients with IBD should be screened for

psychological symptoms and where indicated treated accordingly in the overall management of IBD.

### Acknowledgements

The authors would like to acknowledge support from the EU-FP7 MOODINFLAME consortium. A.A.D. was funded by MOODINFLAME and received a postgraduate fellowship from Trinity College Dublin. C.M. is also supported by Science Foundation Ireland (SFI) – Research Frontier Programme. Authors' Contributions: All authors participated in planning the concept for the review. A.A.D. and E.D. were responsible for initial drafting of the manuscript and collection of data from the available literature. All authors were involved in interpretation of the data collected. All authors critically revised the manuscript. All authors had full access to all of the data obtained from review of the literature and had final responsibility for the decision to submit for publication.

### Conflicts of Interest

The authors have no conflicts of interest to declare.

### References

1. VAVRICKA SR, SCHOEPFER A, SCHARL M, LAKATOS PL, NAVARINI A, ROGLER G. Extraintestinal manifestations of inflammatory bowel disease. *Inflamm Bowel Dis* 2015;**21**: 1982–1992.
2. KIM ER, CHANG DK. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. *World J Gastroenterol* 2014;**20**:9872–9881.
3. LENNARD-JONES JE. Classification of inflamm bowel disease. *Scand J Gastroenterol* 1989;**24**(Suppl. 170):2–6.
4. BAUMGART DC, SANDBORN WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. *Lancet* 2007;**369**:1641–1657.
5. LONNFORS S, VERMEIRE S, GRECO M, HOMMES D, BELL C, AVEDANO L. IBD and health-related quality of life – discovering the true impact. *J Crohns Colitis* 2014;**8**: 1281–1286.
6. JOHNSTON RD, LOGAN RF. What is the peak age for onset of IBD? *Inflamm Bowel Dis* 2008;**14**(Suppl. 2):S4–S5.
7. CARTER MJ, LOBO AJ, TRAVIS SPL. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2004;**53**(Suppl. 5):v1–v16.
8. MOWAT C, COLE A, WINDSOR A et al. Guidelines for the management of inflammatory bowel disease in adults. *Gut* 2011;**60**:571–607.
9. HWANG JM, VARMA MG. Surgery for inflammatory bowel disease. *World J Gastroenterol* 2008;**14**:2678–2690.
10. SICA GS, BIANCONE L. Surgery for inflammatory bowel disease in the era of laparoscopy. *World J Gastroenterol* 2013;**19**:2445–2448.
11. CARD T, HUBBARD R, LOGAN RFA. Mortality in inflammatory bowel disease: a population-based cohort study. *Gastroenterology* 2003;**125**:1583–1590.

12. STRAKER M. Ulcerative colitis: recovery of a patient with brief psychiatric treatment. *Can Med Assoc J* 1960;**82**: 1224–1227.
13. DANIELS GE. Psychiatric aspects of ulcerative colitis. *N Engl J Med* 1942;**226**:178–184.
14. SULLIVAN AJ, CHANDLER CA. Ulcerative colitis of psychogenic origin: a report of six cases. *Yale J Biol Med* 1932;**4**:779–796.
15. MURRAY CD. Psychogenic factors in the etiology of ulcerative colitis and bloody diarrhea. *Am J Med Sci* 1930;**180**:239–247.
16. FARROKHVAR F, MARSHALL JK, EASTERBROOK B, IRVINE EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. *Inflamm Bowel Dis* 2006;**12**:38–46.
17. GUTHRIE E, JACKSON J, SHAFFER J, THOMPSON D, TOMENSON B, CREED F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. *Am J Gastroenterol* 2002;**97**:1994–1999.
18. ADDOLORATO G, CAPRISTO E, STEFANINI GF, GASBARRINI G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. *Scand J Gastroenterol* 1997;**32**: 1013–1021.
19. MIKOCCA-WALUS A, KNOWLES SR, KEEFER L, GRAFF L. Controversies revisited: a systematic review of the comorbidity of depression and anxiety with inflammatory bowel diseases. *Inflamm Bowel Dis* 2016;**22**:752–762.
20. GANDHI S, JEDEL S, HOOD MM, MUTLU E, SWANSON G, KESHAVARZIAN A. The relationship between coping, health competence and patient participation among patients with inactive inflammatory bowel disease. *J Crohns Colitis* 2014;**8**:401–408.
21. GOODHAND JR, WAHED M, MAWDSLEY JE, FARMER AD, AZIZ Q, RAMPTON DS. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. *Inflamm Bowel Dis* 2012;**18**: 2301–2309.
22. ADDOLORATO G, MIRIJELLO A, D'ANGELO C et al. State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. *Int J Clin Pract* 2008;**62**:1063–1069.
23. CALVET X, GALLARDO O, CORONAS R et al. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. *Inflamm Bowel Dis* 2006;**12**:692–696.
24. CLARK JG, SRINATH AI, YOUK AO et al. Predictors of depression in youth with Crohn disease. *J Pediatr Gastroenterol Nutr* 2014;**58**:569–573.
25. BOKEMEYER B, HARDT J, HUPPE D et al. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry. *J Crohns Colitis* 2013;**7**:355–368.
26. BEN THABET J, CHARFI N, MNIF L et al. Emotional disorders and inflammatory bowel disease. *Tuni Med* 2012;**90**: 557–563.
27. CAWTHORPE D, DAVIDSON M. Temporal comorbidity of mental disorder and ulcerative colitis. *Perm J* 2015;**19**: 52–57.
28. HORST S, CHAO A, ROSEN M et al. Treatment with immunosuppressive therapy may improve depressive symptoms in patients with inflammatory bowel disease. *Dig Dis Sci* 2015;**60**:465–470.
29. KEETON RL, MIKOCCA-WALUS A, ANDREWS JM. Concerns and worries in people living with inflammatory bowel disease (IBD): a mixed methods study. *J Psychosom Res* 2015;**78**:573–578.
30. KINSINGER SW, BALLOU S, KEEFER L. Snapshot of an integrated psychosocial gastroenterology service. *World J Gastroenterol* 2015;**21**:1893–1899.
31. LONG MD, KAPPELMAN MD, MARTIN CF, CHEN W, ANTON K, SANDLER RS. Risk factors for depression in the elderly inflammatory bowel disease population. *J Crohns Colitis* 2014;**8**:113–119.
32. MACONI G, GRIDAVILLA D, VIGANO C et al. Perianal disease is associated with psychiatric co-morbidity in Crohn's disease in remission. *Int J Colorectal Dis* 2014;**29**:1285–1290.
33. SZIGETHY E, BUJOREANU SI, YOUK AO et al. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. *J Am Acad Child Adolesc Psychiatry* 2014;**53**:726–735.
34. SZIGETHY EM, YOUK AO, BENHAYON D et al. Depression subtypes in pediatric inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2014;**58**:574–581.
35. VIRTA LJ, KOLHO KL. Antidepressant use among paediatric patients with recent-onset inflammatory bowel disease: a nationwide case control study in Finland. *J Paediatr Child Health* 2014;**50**:562–565.
36. VLACHOS II, BARBATIS C, TSOPANOMICHALOU M et al. Correlation between depression, anxiety, and polymorphonuclear cells' resilience in ulcerative colitis: the mediating role of heat shock protein 70. *BMC Gastroenterol* 2014;**14**:77.
37. ANANTHAKRISHNAN AN, KHALILI H, PAN A et al. Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study. *Clin Gastroenterol Hepatol* 2013;**11**:57–62.
38. GULOKSUZ S, WICHERS M, KENIS G et al. Depressive symptoms in Crohn's disease: relationship with immune activation and tryptophan availability. *PloS One* 2013;**8**: e60435.
39. KNOWLES SR, WILSON J, WILKINSON A et al. Psychological well-being and quality of life in Crohn's disease patients with an ostomy: a preliminary investigation. *J Wound Ostomy Continence Nurs* 2013;**40**:623–629.
40. LANGHORST J, HOFSTETTER A, WOLFE F, HAUSER W. Short-term stress, but not mucosal healing nor depression was predictive for the risk of relapse in patients with ulcerative colitis: a prospective 12-month follow-up study. *Inflamm Bowel Dis* 2013;**19**:2380–2386.
41. SCHUMAN SL, GRAEF DM, JANICKE DM, GRAY WN, HOMMEL KA. An exploration of family problem-solving and affective involvement as moderators between disease severity and depressive symptoms in adolescents with inflammatory bowel disease. *J Clin Psychol Med Settings* 2013;**20**:488–496.
42. SELINGER CP, LAL S, EADEN J et al. Better disease specific patient knowledge is associated with greater anxiety in inflammatory bowel disease. *J Crohns Colitis* 2013;**7**: e214–e218.
43. SHIGA H, MIYAZAWA T, KINOUCI Y et al. Life-event stress induced by the Great East Japan Earthquake was associated

- with relapse in ulcerative colitis but not Crohn's disease: a retrospective cohort study. *BMJ Open* 2013;**3**:e002294.
44. BESHARAT S, AMIRIANI T, ROSHANDEL G, BESHARAT M, SEMNANI S, KAMKAR M. Depressive mood and disease activity in inflammatory bowel disease. *Arab Journal Gastroenterol* 2012;**13**:136–138.
  45. GOODHAND JR, GREIG FI, KOODUN Y et al. Do antidepressants influence the disease course in inflammatory bowel disease? A retrospective case-matched observational study. *Inflamm Bowel Dis* 2012;**18**:1232–1239.
  46. LOFTUS EV JR., GUERIN A, YU AP et al. Increased risks of developing anxiety and depression in young patients with Crohn's disease. *Am J Gastroenterol* 2011;**106**:1670–1677.
  47. IGLESIAS M, BARREIRO DE ACOSTA M, VAZQUEZ I et al. Psychological impact of Crohn's disease on patients in remission: anxiety and depression risks. *Rev Esp Enferm Dig* 2009;**101**:249–257.
  48. VIDAL A, GOMEZ-GIL E, SANS M et al. The impact of anxiety and depression on relapse in patients with inflammatory bowel disease. *Med Clin* 2009;**132**:298–302.
  49. VIDAL A, GOMEZ-GIL E, SANS M et al. Health-related quality of life in inflammatory bowel disease patients: the role of psychopathology and personality. *Inflamm Bowel Dis* 2008;**14**:977–983.
  50. WALKER JR, EDIGER JP, GRAFF LA et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. *Am J Gastroenterol* 2008;**103**:1989–1997.
  51. JANKE KH, KLUMP B, GREGOR M, MEISNER C, HAEUSER W. Determinants of life satisfaction in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;**11**:272–286.
  52. PERSOONS P, VERMEIRE S, DEMYTTENAERE K et al. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. *Aliment Pharmacol Ther* 2005;**22**:101–110.
  53. MARDINI HE, KIP KE, WILSON JW. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. *Dig Dis Sci* 2004;**49**:492–497.
  54. MITTERMAIER C, DEJACO C, WALDHOER T et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. *Psychosom Med* 2004;**66**:79–84.
  55. KURINA LM, GOLDACRE MJ, YEATES D, GILL LE. Depression and anxiety in people with inflammatory bowel disease. *J Epidemiol Community Health* 2001;**55**(10):716–720.
  56. LI J, NORGARD B, PRECHT DH, OLSEN J. Psychological stress and inflammatory bowel disease: a follow-up study in parents who lost a child in Denmark. *Am J Gastroenterol* 2004;**99**:1129–1133.
  57. GOLDSMITH DR, RAPAPORT MH, MILLER BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. *Mol Psychiatry* 2016;**21**:1696–1709.
  58. MARGARETTEN M, JULIAN L, KATZ P, YELIN E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. *Int J Clin Rheumatol* 2011;**6**:617–623.
  59. TYRING S, GOTTLIEB A, PAPP K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. *Lancet* 2006;**367**:29–35.
  60. HARE DL, TOUKHSATI SR, JOHANSSON P, JAARMA T. Depression and cardiovascular disease: a clinical review. *Eur Heart J* 2014;**35**:1365–1372.
  61. ANDREOULAKIS E, HYPHANTIS T, KANDYLIS D, IACOVIDES A. Depression in diabetes mellitus: a comprehensive review. *Hippokratia* 2012;**16**:205–214.
  62. BONACCORSO S, MARINO V, BIONDI M, GRIMALDI F, IPPOLITI F, MAES M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. *J Affect Disord* 2002;**72**:237–241.
  63. CAPURON L, RAVAUD A, DANTZER R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. *J Clin Oncol* 2000;**18**:2143–2151.
  64. GRIGOLEIT J-S, KULLMANN JS, WOLF OT et al. Dose-dependent effects of endotoxin on neurobehavioral functions in humans. *PloS One* 2011;**6**:e28330.
  65. REICHENBERG A, YIRMIYA R, SCHULD A et al. Cytokine-associated emotional and cognitive disturbances in humans. *Arch Gen Psychiatry* 2001;**58**:445–452.
  66. KENT S, BLUTHE RM, KELLEY KW, DANTZER R. Sickness behavior as a new target for drug development. *Trends Pharmacol Sci* 1992;**13**:24–28.
  67. EISENBERGER NI, INAGAKI TK, MASHAL NM, IRWIN MR. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. *Brain Behav Immun* 2010;**24**:558–563.
  68. MAES M, BERK M, GOEHLER L et al. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. *BMC Med* 2012;**10**:66.
  69. ZHU H, LI YR. Oxidative stress and redox signaling mechanisms of inflammatory bowel disease: updated experimental and clinical evidence. *Exp Biol Med (Maywood)* 2012;**237**:474–480.
  70. MAES M, KUBERA M, OBUCHOWICZWA E, GOEHLER L, BRZESZCZ J. Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. *Neuro Endocrinol Lett* 2011;**32**:7–24.
  71. KÖHLER O, BENROS ME, NORDENTOF M et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. *JAMA Psychiatry* 2014;**71**:1381–1391.
  72. ENNAIFER R, ELLEUCH N, CHEIKH M et al. Risk factors of psychological disorders in inflammatory bowel disease in a tunisian survey. Results of a cross-sectional study. *Tuni Med* 2014;**92**:723–726.
  73. NAHON S, LAHMEK P, DURANCE C et al. Risk factors of anxiety and depression in inflammatory bowel disease. *Inflamm Bowel Dis* 2012;**18**:2086–2091.
  74. SAINSBURY A, HEATLEY RV. Review article: psychosocial factors in the quality of life of patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2005;**21**:499–508.
  75. ZELINKOVA Z, DER WOUDE C. Gender and inflammatory bowel disease. *J Clin Cell Immunol* 2014;**5**:245–253.
  76. PANARA AJ, YARUR AJ, RIEDERS B et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. *Aliment Pharmacol Ther* 2014;**39**:802–810.
  77. CASELLAS F, LOPEZ-VIVANCOS J, CASADO A, MALAGELADA JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. *Qual Life Res* 2002;**11**:775–781.

78. HAUSER G, TKALČIĆ M, STIMAC D, MILIC S, SINCIC BM. Gender related differences in quality of life and affective status in patients with inflammatory bowel disease. *Coll Antropol* 2011;**35**(Suppl. 2):203–207.
79. BERRILL JW, GREEN JT, HOOD K, CAMPBELL AK. Symptoms of irritable bowel syndrome in patients with inflammatory bowel disease: examining the role of sub-clinical inflammation and the impact on clinical assessment of disease activity. *Aliment Pharmacol Ther* 2013;**38**:44–51.
80. NORTON C, CZUBER-DOCHAN W, BASSETT P et al. Assessing fatigue in inflammatory bowel disease: comparison of three fatigue scales. *Aliment Pharmacol Ther* 2015;**42**:203–211.
81. LIMA FD, RIBEIRO TC, CHEBLI LA et al. Mood swings in patients with Crohn's disease: incidence and associated factors. *Rev Assoc Med Bras (1992)* 2012;**58**:481–488.
82. HOU JK, ABRAHAM B, EL-SERAG H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *Am J Gastroenterol* 2011;**106**:563–573.
83. OLENDZKI BC, SILVERSTEIN TD, PERSUITTE GM, MA Y, BALDWIN KR, CAVE D. An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report. *Nutr J* 2014;**13**:5.
84. DEBERRY JJ, BIELEFELDT K, DAVIS BM, SZIGETHY EM, HARTMAN DJ, COATES MD. Abdominal pain and the neurotrophic system in ulcerative colitis. *Inflamm Bowel Dis* 2014;**20**:2330–2339.
85. SRINATH AI, GOYAL A, ZIMMERMAN LA et al. Predictors of abdominal pain in depressed pediatric inflammatory bowel disease patients. *Inflamm Bowel Dis* 2014;**20**:1329–1340.
86. GOYAL N, RANA A, AHLAWAT A, BIJEM KR, KUMAR P. Animal models of inflammatory bowel disease: a review. *Inflammopharmacology* 2014;**22**:219–233.
87. OKAYASU I, HATAKEYAMA S, YAMADA M, OHKUSA T, INAGAKI Y, NAKAYA R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. *Gastroenterology* 1990;**98**:694–702.
88. GAUDIO E, TADDEI G, VETUSCHI A et al. Dextran sulfate sodium (DSS) colitis in rats: clinical, structural, and ultrastructural aspects. *Dig Dis Sci* 1999;**44**:1458–1475.
89. MORRIS GP, BECK PL, HERRIDGE MS, DEPEW WT, SZEWCZUK MR, WALLACE JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. *Gastroenterology* 1989;**96**:795–803.
90. BOUMA G, STROBER W. The immunological and genetic basis of inflammatory bowel disease. *Nat Rev Immunol* 2003;**3**:521–533.
91. NELL S, SUERBAUM S, JOSEPHANS C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. *Nat Rev Microbiol* 2010;**8**:564–577.
92. MANSFIELD LS, BELL JA, WILSON DL et al. C57BL/6 and congenic interleukin-10-deficient mice can serve as models of *Campylobacter jejuni* colonization and enteritis. *Infect Immun* 2007;**75**:1099–1115.
93. O'MAHONY SM, HYLAND NP, DINAN TG, CRYAN JF. Maternal separation as a model of brain-gut axis dysfunction. *Psychopharmacology* 2011;**214**:71–88.
94. REBER SO, BIRKENEDER L, VEENEMA AH et al. Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice: implications and mechanisms. *Endocrinology* 2007;**148**:670–682.
95. REBER SO, OBERMEIER F, STRAUB RH, VEENEMA AH, NEUMANN ID. Aggravation of DSS-induced colitis after chronic subordinate colony (CSC) housing is partially mediated by adrenal mechanisms. *Stress* 2008;**11**:225–234.
96. VICARIO M, GUILARTE M, ALONSO C et al. Chronological assessment of mast cell-mediated gut dysfunction and mucosal inflammation in a rat model of chronic psychosocial stress. *Brain Behav Immun* 2010;**24**:1166–1175.
97. HEYDARPOUR P, RAHIMIAN R, FAKHFOURI G et al. Behavioral despair associated with a mouse model of Crohn's disease: role of nitric oxide pathway. *Prog Neuropsychopharmacol Biol Psychiatry* 2016;**64**:131–141.
98. CHEN J, WINSTON JH, FU Y et al. Genesis of anxiety, depression, and ongoing abdominal discomfort in ulcerative colitis-like colon inflammation. *Am J Physiol Regul Integr Comp Physiol* 2015;**308**:R18–R27.
99. MESSAOUDI M, DESOR D, GRASMUCK V, JOYEUX M, LANGLOIS A, ROMAN FJ. Behavioral evaluation of visceral pain in a rat model of colonic inflammation. *Neuroreport* 1999;**10**:1137–1141.
100. PAINSIPP E, HERZOG H, SPERK G, HOLZER P. Sex-dependent control of murine emotional-affective behaviour in health and colitis by peptide YY and neuropeptide Y. *Br J Pharmacol* 2011;**163**:1302–1314.
101. LYTE M, LI W, OPITZ N, GAYKEMA RP, GOEHLER LE. Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia *Citrobacter rodentium*. *Physiol Behav* 2006;**89**:350–357.
102. GAREAU MG, WINE E, RODRIGUES DM et al. Bacterial infection causes stress-induced memory dysfunction in mice. *Gut* 2011;**60**:307–317.
103. EMGE JR, HUYNH K, MILLER EN et al. Modulation of the microbiota-gut-brain axis by probiotics in a murine model of inflammatory bowel disease. *Am J Physiol Gastrointest Liver Physiol* 2016;**310**:G989–G998.
104. BERCIK P, PARK AJ, SINCLAIR D et al. The anxiolytic effect of *Bifidobacterium longum* NCC3001 involves vagal pathways for gut-brain communication. *Neurogastroenterol Motil* 2011;**23**:1132–1139.
105. FRENOIS F, MOREAU M, O'CONNOR J et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. *Psychoneuroendocrinology* 2007;**32**:516–531.
106. MAYHAN WG, ARRICK DM. eds. *The Blood-Brain Barrier in Health and Disease. Colloquium Series on Integrated Systems Physiology: From Molecule to Function to Disease.* Morgan & Claypool Life Sciences, San Rafael, CA, USA, 2016.
107. VARATHARAJ A, GALEA I. The blood-brain barrier in systemic inflammation. *Brain Behav Immun* 2017;**60**:1–12.
108. HATHAWAY CA, APLEYARD CB, PERCY WH, WILLIAMS JL. Experimental colitis increases blood-brain barrier permeability in rabbits. *Am J Physiol* 1999;**276**(Pt 1):G1174–G1180.
109. HATHAWAY CA, PERCY WH, WILLIAMS JL. Effects of free radicals and leukocytes on increases in blood-brain barrier permeability during colitis. *Dig Dis Sci* 2000;**45**:967–975.
110. NATAH SS, MOUHATE A, PITTMAN QJ, SHARKEY KA. Disruption of the blood-brain barrier during TNBS colitis. *Neurogastroenterol Motil* 2005;**17**:433–446.
111. SANS M, KAWACHI S, SORIANO A et al. Brain endothelial adhesion molecule expression in experimental colitis. *Microcirculation* 2001;**8**:105–114.



112. NEURATH MF. Cytokines in inflammatory bowel disease. *Nat Rev Immunol* 2014;**14**:329–342.
113. LEONARD B, MAES M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. *Neurosci Biobehav Rev* 2012;**36**:764–785.
114. RIAZI K, GALIC MA, KUZMISKI JB, HO W, SHARKEY KA, PITTMAN QJ. Microglial activation and TNF $\alpha$  production mediate altered CNS excitability following peripheral inflammation. *Proc Natl Acad Sci USA* 2008;**105**:17151–17156.
115. MEDHI B, PRAKASH A, AVTI PK, CHAKRABARTI A, KHANDUJA KL. Intestinal inflammation and seizure susceptibility: understanding the role of tumour necrosis factor- $\alpha$  in a rat model. *J Pharm Pharmacol* 2009;**61**:1359–1364.
116. WANG K, YUAN CP, WANG W et al. Expression of interleukin 6 in brain and colon of rats with TNBS-induced colitis. *World J Gastroenterol* 2010;**16**:2252–2259.
117. BATICIC L, DETEL D, KUCIC N, BULJEVIC S, PUGEL EP, VARLIJEN J. Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice. *J Cell Biochem* 2011;**112**:3322–3333.
118. ALHOUAYEK M, LAMBERT DM, DELZENNE NM, CANI PD, MUCCIOLI GG. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. *FASEB J* 2011;**25**:2711–2721.
119. VILLARAN RF, ESPINOSA-OLIVA AM, SARMIENTO M et al. Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. *J Neurochem* 2010;**114**:1687–1700.
120. REICHMANN F, HASSAN AM, FARZI A, JAIN P, SCHULIGOI R, HOLZER P. Dextran sulfate sodium-induced colitis alters stress-associated behaviour and neuropeptide gene expression in the amygdala-hippocampus network of mice. *Sci Rep* 2015;**5**:9970.
121. BECHER B, SPATH S, GOVERMAN J. Cytokine networks in neuroinflammation. *Nat Rev Immunol* 2017;**17**:49–59.
122. HANISCH UK. Microglia as a source and target of cytokines. *Glia* 2002;**40**:140–155.
123. SOFRONIEW MV. Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. *Neuroscientist* 2014;**20**:160–172.
124. DANTZER R, O'CONNOR JC, FREUND GG, JOHNSON RW, KELLEY KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008;**9**:46–56.
125. KHAIROVA RA, MACHADO-VIEIRA R, DU J, MANJI HK. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. *Int J Neuropsychopharmacol* 2009;**12**:561–578.
126. STELLWAGEN D, MALENKA RC. Synaptic scaling mediated by glial TNF- $\alpha$ . *Nature* 2006;**440**:1054–1059.
127. MILLER AH, HAROON E, RAISON CL, FELGER JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. *Depress Anxiety* 2013;**30**:297–306.
128. O'CONNOR JC, ANDRE C, WANG Y et al. Interferon- $\gamma$  and tumor necrosis factor- $\alpha$  mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. *J Neurosci* 2009;**29**:4200–4209.
129. DUNN AJ. Cytokine activation of the HPA axis. *Ann N Y Acad Sci* 2000;**917**:608–617.
130. MILLER AH, PARIANTE CM, PEARCE BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. *Adv Exp Med Biol* 1999;**461**:107–116.
131. PARIANTE CM, LIGHTMAN SL. The HPA axis in major depression: classical theories and new developments. *Trends Neurosci* 2008;**31**:464–468.
132. KIM YK, NA KS, MYINT AM, LEONARD BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2016;**64**:277–284.
133. KOVACS KJ. Measurement of immediate-early gene activation-c-fos and beyond. *J Neuroendocrinol* 2008;**20**:665–672.
134. OKUNO H. Regulation and function of immediate-early genes in the brain: beyond neuronal activity markers. *Neurosci Res* 2011;**69**:175–186.
135. MIAMPAMBA M, SHARKEY KA. c-Fos expression in the myenteric plexus, spinal cord and brainstem following injection of formalin in the rat colonic wall. *J Auton Nerv Sys* 1999;**77**:140–151.
136. PORCHER C, SINNIGER V, JUHEM A, MOUCHET P, BONAZ B. Neuronal activity and CRF receptor gene transcription in the brains of rats with colitis. *Am J Physiol Gastrointest Liver Physiol* 2004;**287**:G803–G814.
137. HSIAO EY. Gastrointestinal issues in autism spectrum disorder. *Harv Rev Psychiatry* 2014;**22**:104–111.
138. WELCH MG, WELCH-HORAN TB, ANWAR M, ANWAR N, LUDWIG RJ, RUGGIERO DA. Brain effects of chronic IBD in areas abnormal in autism and treatment by single neuropeptides secretin and oxytocin. *J Mol Neurosci* 2005;**25**:259–274.
139. WELCH MG, ANWAR M, CHANG CY et al. Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons. *Neurogastroenterol Motil* 2010;**22**:e654–e202.
140. GOEHLER LE, GAYKEMA RP, OPITZ N, REDDAWAY R, BADR N, LYTE M. Activation in vagal afferents and central autonomic pathways: early responses to intestinal infection with *Campylobacter jejuni*. *Brain Behav Immun* 2005;**19**:334–344.
141. DAVE M, HIGGINS PD, MIDDHA S, RIOUX KP. The human gut microbiome: current knowledge, challenges, and future directions. *Transl Res* 2012;**160**:246–257.
142. FRANK DN, ST AMAND AL, FELDMAN RA, BOEDEKER EC, HARPAZ N, PACE NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *Proc Natl Acad Sci USA* 2007;**104**:13780–13785.
143. JANDHYALA SM, TALUKDAR R, SUBRAMANYAM C, VUYUYURU H, SASIKALA M, REDDY DN. Role of the normal gut microbiota. *World J Gastroenterol* 2015;**21**:8787–8803.
144. JOSTINS L, RIPKE S, WEERSMA RK et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature* 2012;**491**:119–124.
145. NITZAN O, ELIAS M, PERETZ A, SALIBA W. Role of antibiotics for treatment of inflammatory bowel disease. *World J Gastroenterol* 2016;**22**:1078–1087.
146. SELLON RK, TONKONOGY S, SCHULTZ M et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in

- interleukin-10-deficient mice. *Infect Immun* 1998;**66**: 5224–5231.
147. SHERWIN E, SANDHU KV, DINAN TG, CRYAN JF. May the force be with you: the light and dark sides of the microbiota-gut-brain axis in neuropsychiatry. *CNS Drugs* 2016;**30**:1019–1041.
  148. FULLER R. Probiotics: the scientific basis. *Gut* 1993;**34**: 863–864.
  149. GIBSON GR, ROBERFROID MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* 1995;**125**:1401–1412.
  150. MALLON P, MCKAY D, KIRK S, GARDINER K. Probiotics for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2007;**4**:Cd005573.
  151. RAHIMI R, NIKFAR S, RAHIMI F et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. *Dig Dis Sci* 2008;**53**:2524–2531.
  152. CASELLAS F, BORRUEL N, TORREJON A et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. *Aliment Pharmacol Ther* 2007;**25**:1061–1067.
  153. BAMBA T, KANAUCHI O, ANDOH A, FUJIYAMA Y. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. *J Gastroenterol Hepatol* 2002;**17**:818–824.
  154. KANAUCHI O, SUGA T, TOCHIHARA M et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. *J Gastroenterol* 2002;**37**(Suppl. 14):67–72.
  155. BENJAMIN JL, HEDIN CR, KOUTSOUMPAS A et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. *Gut* 2011;**60**:923–929.
  156. LINDSAY JO, WHELAN K, STAGG AJ et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. *Gut* 2006;**55**:348–355.
  157. MESSAOUDI M, LALONDE R, VIOLLE N et al. Assessment of psychotropic-like properties of a probiotic formulation (*Lactobacillus helveticus* R0052 and *Bifidobacterium longum* R0175) in rats and human subjects. *Br J Nutr* 2011;**105**:755–764.
  158. RAO AV, BESTED AC, BEAULNE TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. *Gut Pathog* 2009;**1**:6.
  159. SCHMIDT K, COWEN PJ, HARMER CJ, TZORTZIS G, ERRINGTON S, BURNET PW. Probiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. *Psychopharmacology* 2015;**232**:1793–1801.
  160. COLMAN RJ, RUBIN DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohns Colitis* 2014;**8**:1569–1581.
  161. MOAYYEDI P, SURETTE MG, KIM PT et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. *Gastroenterology* 2015;**149**:102–109.e6.
  162. ROSSEN NG, FUENTES S, VAN DER SPEK MJ et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. *Gastroenterology* 2015;**149**:110–118.e4.
  163. KELLY JR, BORRE Y, O'BRIEN C, PATTERSON E et al. Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. *J Psychiatr Res* 2016;**82**:109–118.
  164. HEIJTZ RD, WANG S, ANUAR F et al. Normal gut microbiota modulates brain development and behavior. *Proc Natl Acad Sci USA* 2011;**108**:3047–3052.
  165. BERCIK P, PARK AJ, SINCLAIR D, KHOSHDEL A, LU J, HUANG X. The anxiolytic effect of *Bifidobacterium longum* NCC3001 involves vagal pathways for gut-brain communication. *Neurogastroenterol Motil* 2011;**23**:1132–1139.
  166. GOEHLER LE, PARK SM, OPITZ N, LYTE M, GAYKEMA RP. *Campylobacter jejuni* infection increases anxiety-like behavior in the holeboard: possible anatomical substrates for viscerosensory modulation of exploratory behavior. *Brain Behav Immun* 2008;**22**:354–366.
  167. BRAVO JA, FORSYTHE P, CHEW MV et al. Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. *Proc Natl Acad Sci USA* 2011;**108**:16050–16055.
  168. DESBONNET L, GARRETT L, CLARKE G, KIELY B, CRYAN JF, DINAN TG. Effects of the probiotic *Bifidobacterium infantis* in the maternal separation model of depression. *Neuroscience* 2010;**170**:1179–1188.
  169. ZONIS S, PECHNICK RN, LJUBIMOV VA et al. Chronic intestinal inflammation alters hippocampal neurogenesis. *J Neuroinflammation* 2015;**12**:1–12.
  170. KONTUREK PC, BRZozowski T, KONTUREK SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. *J Physiol Pharmacol* 2011;**62**:591–599.
  171. DENG Q, CHEN H, LIU Y et al. Psychological stress promotes neutrophil infiltration in colon tissue through adrenergic signaling in DSS-induced colitis model. *Brain Behav Immun*. 2016;**30**:243–254.
  172. WOOD JD, PECK OC, TEFEND KS et al. Evidence that colitis is initiated by environmental stress and sustained by fecal factors in the cotton-top tamarin (*Saguinus oedipus*). *Dig Dis Sci* 2000;**45**:385–393.
  173. MILDE AM, MURISON R. A study of the effects of restraint stress on colitis induced by dextran sulphate sodium in singly housed rats. *Integr Physiol Behav Sci* 2002;**37**:140–150.
  174. MILDE AM, ARSLAN G, OVERMIER JB, BERSTAD A, MURISON R. An acute stressor enhances sensitivity to a chemical irritant and increases 51CrEDTA permeability of the colon in adult rats. *Integr Physiol Behav Sci* 2005;**40**:35–44.
  175. PETERS S, GRUNWALD N, RUMMELE P et al. Chronic psychosocial stress increases the risk for inflammation-related colon carcinogenesis in male mice. *Stress* 2012;**15**:403–415.
  176. GREENWOOD-VAN MEERVELD B, JOHNSON AC, SCHULKIN J, MYERS DA. Long-term expression of corticotropin-releasing factor (CRF) in the paraventricular nucleus of the hypothalamus in response to an acute colonic inflammation. *Brain Res* 2006;**1071**:91–96.
  177. KOJIMA K, NARUSE Y, IJIMA N et al. HPA-axis responses during experimental colitis in the rat. *Am J Physiol Regul Integr Comp Physiol* 2002;**282**:R1348–R1355.
  178. AGOSTINI A, FILIPPINI N, CEVOLANI D et al. Brain functional changes in patients with ulcerative colitis: a functional magnetic resonance imaging study on emotional processing. *Inflamm Bowel Dis* 2011;**17**:1769–1777.
  179. AGOSTINI A, FILIPPINI N, BENUZZI F et al. Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. *J Behav Med* 2013;**36**:477–487.